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The Role And Mechanism Of Transforming Growth Factor Beta 1 In Airway
Hyperresponsiveness
Abstract
Asthma, a chronic inflammatory airway disease characterized by airway hyperresponsiveness (AHR) and
airway remodeling, affects 300 million people worldwide. Conventional asthma management includes the
use of glucocorticoids and β2-agonist bronchodilators to combat inflammation and reverse airway
narrowing. In severe asthma patients, whose asthma is poorly controlled with conventional therapies,
frequent asthma exacerbations can lead to sustained AHR that remains insensitive to bronchodilator
therapy. Therefore, it is essential to determine the mechanisms contributing to AHR and irreversible
airflow obstruction in asthma to reduce patient morbidity and mortality. Transforming growth factor beta
1 (TGF-β1), a growth factor elevated in the airway of patients with asthma, perpetuates airway
inflammation and airway remodeling in airway structural cells. The role of TGF-β1 in mediating AHR,
however, remains unclear. In this dissertation, we demonstrate that TGF-β1 primes agonist-induced
contractile responses and attenuates agonist-induced relaxation pathways in human airway smooth
muscle (HASM), contributing to AHR and irreversible airflow obstruction in asthma. The dynamics of AHR
and single-cell excitation-contraction coupling were measured using supravital microscopy, magnetic
twisting cytometry, and biochemical assays in human precision-cut lung slices (hPCLS) and isolated
primary HASM cells. We demonstrate that overnight TGF-β1 treatment augmented basal and agonistinduced shortening in hPCLS and isolated HASM cells. Interestingly, TGF-β1 increased HASM cell
shortening and myosin light chain phosphorylation in a Smad3-dependent manner, with little effect on
intracellular calcium levels. Additionally, we find that overnight TGF-β1 treatment decreased β2-agonistinduced relaxation responses in HASM cells via induction of phosphodiesterase 4 (PDE4), an enzyme that
negatively regulates β2-agonist signaling pathways. Pharmacological and siRNA inhibition of PDE4 and
Smad3, respectively, restored β2-agonist sensitivity in TGF-β1-treated HASM cells. Together, our data
suggest that increased levels of TGF-β1 in the airway contribute to airway narrowing, asthma
exacerbations, and bronchodilator resistance in asthma. Furthermore, our results establish TGF-β1 as a
novel therapeutic target to decrease airway exacerbations in patients with severe and treatment-resistant
asthma.
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ABSTRACT

THE ROLE AND MECHANISM OF TRANSFORMING GROWTH FACTOR BETA 1 IN
AIRWAY HYPERRESPONSIVENESS

Christie A. Ojiaku
Dr. Reynold A. Panettieri, Jr.

Asthma,

a

chronic

inflammatory

airway

disease

characterized

by

airway

hyperresponsiveness (AHR) and airway remodeling, affects 300 million people
worldwide. Conventional asthma management includes the use of glucocorticoids and
β2-agonist bronchodilators to combat inflammation and reverse airway narrowing. In
severe asthma patients, whose asthma is poorly controlled with conventional therapies,
frequent asthma exacerbations can lead to sustained AHR that remains insensitive to
bronchodilator therapy. Therefore, it is essential to determine the mechanisms
contributing to AHR and irreversible airflow obstruction in asthma to reduce patient
morbidity and mortality. Transforming growth factor beta 1 (TGF-β1), a growth factor
elevated in the airway of patients with asthma, perpetuates airway inflammation and
airway remodeling in airway structural cells. The role of TGF-β1 in mediating AHR,
however, remains unclear. In this dissertation, we demonstrate that TGF-β1 primes
agonist-induced contractile responses and attenuates agonist-induced relaxation
pathways in human airway smooth muscle (HASM), contributing to AHR and irreversible
airflow obstruction in asthma. The dynamics of AHR and single-cell excitationcontraction coupling were measured using supravital microscopy, magnetic twisting
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cytometry, and biochemical assays in human precision-cut lung slices (hPCLS) and
isolated primary HASM cells. We demonstrate that overnight TGF-β1 treatment
augmented basal and agonist-induced shortening in hPCLS and isolated HASM cells.
Interestingly, TGF-β1 increased HASM cell shortening and myosin light chain
phosphorylation in a Smad3-dependent manner, with little effect on intracellular calcium
levels. Additionally, we find that overnight TGF-β1 treatment decreased β2-agonistinduced relaxation responses in HASM cells via induction of phosphodiesterase 4
(PDE4), an enzyme that negatively regulates β2-agonist signaling pathways.
Pharmacological and siRNA inhibition of PDE4 and Smad3, respectively, restored β2agonist sensitivity in TGF-β1-treated HASM cells. Together, our data suggest that
increased levels of TGF-β1 in the airway contribute to airway narrowing, asthma
exacerbations, and bronchodilator resistance in asthma. Furthermore, our results
establish TGF-β1 as a novel therapeutic target to decrease airway exacerbations in
patients with severe and treatment-resistant asthma.
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Asthma and Airway Smooth Muscle

Asthma, a chronic inflammatory disease that affects approximately 300 million
people worldwide (1), is a significant source of global morbidity and mortality. Asthma
presents a substantial economic and financial burden to industrialized and developing
countries (2), with direct healthcare costs reaching approximately $50 billion annually in
the United States alone (3). The management of asthma includes inhaled
glucocorticoids to combat inflammation and β2-agonist bronchodilators to reverse airway
smooth muscle (ASM) bronchoconstriction. Approximately 50% of asthma patients,
however, experience inadequate control with current therapeutics (4). Due to the
increasing prevalence and per-patient costs of asthma (5), an urgent need exists to
determine therapeutic targets to reduce asthma-related morbidity.
Airway remodeling and airway hyperresponsiveness (AHR) are two defining
characteristics of asthma. Airway remodeling - defined as cellular and molecular
architecture changes that manifest as structural alterations in the airway wall – may be a
major contributor to lung function decline in asthma (6). AHR is governed by the
contraction of ASM – the key regulator of bronchomotor tone – and is defined as
exaggerated narrowing of the airway to stimuli (7, 8). While studies show a connection
between airway remodeling and changes in bronchomotor tone, the relationship
between the two remains unclear.
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Airway Remodeling and Airway Hyperresponsiveness – A Direct Relation?

Airway remodeling and sustained AHR in asthma are closely correlated. The
mechanisms by which each exacerbates the other - or whether a direct connection
exists between the two - remain highly debated. While airway inflammation is suggested
to precede the development of both pathologies (9, 10), airway structural alterations may
also independently modify AHR (11, 12). It is suggested that frequent asthma
exacerbations evoke an airway injury-repair cycle that promotes sustained AHR by
altering the structure and function of ASM cells (13, 14). Additionally, recent literature
suggests an uncoupling of airway inflammation and AHR in asthma (9, 11, 15, 16).
Understandably, the link between injury-repair responses and AHR remains unclear.
TGF-β1 - a cytokine elevated in the airway of patients with asthma (17, 18) contributes to airway structural cell remodeling in asthma (19, 20). In addition to
facilitating structural cell remodeling, TGF-β1 may participate in airway narrowing by
increasing ASM contractile protein expression (21). Conversely, the act of ASM
shortening alone activates TGF-β1 signaling. Agonist-induced ASM bronchoconstriction
(22) and myofibroblast contraction (23) induce the release of active TGF-β1, which may
augment both airway remodeling and airway narrowing. Furthermore, challenge with the
contractile agonist methacholine induces active TGF-β1 release and airway remodeling
without affecting airway eosinophil recruitment, suggesting an uncoupling of airway
inflammation from both AHR and remodeling (24). Thus, TGF-β1 is emerging as a
potential target mediating the connection between airway remodeling and AHR in
asthma. In this literature review, we will investigate TGF-β1’s role in airway remodeling
and AHR in order to determine the joint position of TGF-β1 in both arms of asthma
3

pathogenesis, and examine targeting the TGF-β1 signaling pathway as a therapeutic for
asthma-related illness.
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Asthma Therapeutics: Mechanisms of Action and Limitations

Mainstay asthma therapeutics include the use of glucocorticoids, which combat
airway inflammation, and bronchodilators, which induce airway relaxation. β2-agonist
bronchodilators

are

used

as

a

first-line

therapeutic

to

counteract

airway

bronchoconstriction in asthma. β2-agonists bind to the Gαs-coupled β2 adrenergic
receptor (β2AR) on the HASM cell membrane, leading to adenylyl cyclase activation and
elevated cyclic adenosine monophosphate (cAMP) levels in the cell. Elevated cAMP
activates cAMP-dependent protein kinase A (PKA), a kinase that induces HASM cell
relaxation by phosphorylating and inhibiting HASM contractile pathway components.
While β2-agonists are highly effective bronchodilators, patients with severe
asthma are often resistant to β2-agonist therapy (25, 26). Additionally, prolonged and/or
frequent β2-agonist use can lead to bronchodilator resistance (26–28), increased
morbidity and mortality (29, 30), and increased asthma exacerbations (31). While the
mechanisms underlying these phenomena remain unclear, evidence suggests that β2AR
desensitization may play a role (32, 33).
In addition to β2-agonists, glucocorticoids are a mainstay therapy used in asthma
to combat airway inflammation. Patients with severe asthma, however, exhibit
decreased sensitivity to glucocorticoid-mediated inflammation control (34). Additionally,
while glucocorticoid use attenuates airway structural cell remodeling in vitro, little
evidence suggests that glucocorticoid or β2-agonists reverse the long-term airway
remodeling that contributes to airway obstruction and disease progression (35). Although
recently developed monoclonal antibodies may directly or indirectly work to decrease
airway remodeling by targeting key inflammatory mediators, further studies will be
5

needed to determine the anti-remodeling effects of these therapeutics. Due to the
limitations of current therapies, it will be essential to determine novel targets to decrease
therapeutic resistance and slow disease progression in asthma.
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TGF-β1 Signaling

Transforming growth factor beta 1 (TGF-β1) is a growth factor and cytokine
involved extensively in the pathogenesis of asthma and other airway diseases. TGF-β1
belongs to a family of growth factors that bind to TβR-I and TβR-II receptors. These
members include TGF-β2 and TGF-β3 as well as the bone morphogenic protein (BMP)
kinases. TGF-β1 is synthesized in a latent form that is secreted into the extracellular
space or held near the extracellular matrix by integrins (36) (Figure 1). Latent TGF-β1
can be activated by integrins, reactive oxygen species (ROS), mechanical stress, and
other mechanisms as shown in Table 1.
Canonical TGF-β1 signaling begins when activated TGF-β1 binds to the serinethreonine kinase TGF-β Type II Receptor (TβR-II) (Figure 1). Subsequently, TβR-II
recruits and phosphorylates TGF-β Type I Receptor (TβR-I) at serine/threonine residues.
Activated TβR-I then phosphorylates Smad2 and Smad3 (Smad2/3) transcription factors.
Following association with Smad4, the phosphorylated Smad complex translocates to
the nucleus to promote the transcription of target genes (37, 38). The Smad complex
binds to DNA directly or indirectly via interaction with other proteins, recruiting coactivators to mediate the transcription of genes involved in a variety of pathways (39).
Additionally, TGF-β1 signals through a variety of diverse, Smad-independent pathways
that modulate [Ca2+]i levels (40, 41), RhoA/ROCK Kinase (ROCK) (42), MAPK and ERK
pathways (43, 44). Both Smad-independent and –dependent pathways may mediate
airway remodeling and AHR.
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TGF-β1 and Airway Disease

TGF-β1 promotes the pathogenesis of several airway diseases involving
inflammation and remodeling, including chronic obstructive pulmonary disease,
parenchymal lung diseases, and asthma. Active TGF-β1 is found elevated in the
bronchoalveolar lavage fluid (17) and in bronchial biopsy samples (18) taken from
asthmatic subjects. Additionally, TGF-β1 expression is elevated in the bronchial
epithelium (45), submucosa, subepithelial connective tissue, subepithelium, and ASM of
subjects with asthma (18, 46). While it is unclear which structural cell produces the
majority of TGF-β1 in the airway, epithelial-derived TGF-β1 is suggested to be an
important contributor to asthma pathogenesis (47). However, much of the elevation of
TGF-β1 in the airway of asthmatic subjects may result from the secretion of TGF-β1 by
invading inflammatory cells in asthma (48–50), with eosinophils accounting for the
largest source of TGF-β1 in the airway (49).
TGF-β1 itself plays a significant and complex role in the airway immune
response, mediating a variety of pro-inflammatory or immunosuppressive effects. TGFβ1 stimulates the recruitment of inflammatory cells to the airway and promotes the
secretion of additional growth factors and inflammatory cytokines (51, 52). Conversely,
TGF-β1 can suppress both lymphocyte proliferation (53, 54) and the production of
certain cytokines (55). While the detailed role of TGF-β1 in airway inflammation will not
be covered in this thesis, the participation of TGF-β1 in all aspects of asthma
pathogenesis – inflammation, remodeling, and AHR – elevates the potential benefit of
targeting the TGF-β1 signaling pathway to reduce asthma morbidity and mortality.
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TGF-β1 and Airway Disease: Airway Remodeling and Proliferation

TGF-β1 contributes to airway remodeling in asthma by mediating the
differentiation, proliferation, apoptosis, and size of structural cells in the airway (19).
These reversible or partially irreversible modifications alter the composition of the airway
wall, contributing to luminal diameter narrowing in asthma (13, 56). Furthermore, studies
suggest that alterations in airway structural cell size or accumulation can influence AHR
(57, 58). In this section, we will identify mechanisms underlying the fibrosis,
differentiation, proliferation, and apoptosis involved in TGF-β1-induced airway structural
cell remodeling.

Fibrosis
TGF-β1 promotes airway structural cell fibrosis in asthma through various
mechanisms. TGF-β1 mediates the expression of genes implicated in fibrosis – including
collagen (59), proteases (60), and fibronectin (61) - through a Smad-dependent
mechanism. Additionally, TGF-β1 may mediate a subset of its fibrotic effects through the
production of ROS generated by the mitochondrial electron transport chain (62) and the
ROS-producing enzyme NADPH Oxidase 4 (NOX4) (63).
TGF-β1 may also mediate pulmonary fibrosis through the induction of endothelin1 (64) - a vasoconstrictor peptide induced by Smad-independent (65) or –dependent
(66) mechanisms following TGF-β1 exposure. Interestingly, investigations have
demonstrated a role for TGF-β1-induced endothelin-1 in AHR pathogenesis (67),
suggesting another mechanism by which dysregulation of TGF-β1 signaling may
9

contribute to airway bronchoconstriction. In addition to endothelin-1 induction, TGF-β1
may induce fibrosis by activating caspases that mediate cell death and apoptosis. In one
study, investigators found that Bax and Bid - two apoptotic regulatory proteins suggested
to mediate fibrotic responses (68, 69) – may be activated by TGF-β1 and facilitate
bleomycin-induced pulmonary fibrosis in mice (70). In this study, TGF-β1-mediated
increases in inflammation, lung collagen content and lung cell apoptosis were
significantly decreased in both Bax- and Bid-null mice versus wild-type control.
Additionally, TGF-β1-induced matrix metalloproteinase-12 (MMP-12) expression was
inhibited in Bax and Bid-null mice, suggesting a role for MMP-12 in the Bid and Baxmediated induction of fibrotic responses by TGF-β1.
Activation of TGF-β1 by integrins is pivotal in mediating the fibrotic response. The
∂Vß8 integrin in epithelial cells activates TGF-β1 through matrix metalloproteinase-14
(MMP-14) and proteolytic cleavage of latent TGF-β1 into active TGF-β1 (71). Activation
of TGF-β1 can also occur through the integrins ∂Vß3, ∂Vß5, and ∂Vß6 by way of cellular
contraction and the cellular cytoskeleton as shown in Table 1. The avß6 integrin - whose
expression is increased in injured epithelia (72) - is constitutively bound to TGF-β1 and
can be induced by lysophosphatidic acid (LPA) or thrombin-mediated changes in the
cytoskeleton (73). Furthermore, activation of avß6 may modulate AHR by altering the
expression of mast cell proteases that can contribute to or inhibit airway narrowing (74).
Additionally, furin proteases can cleave latent TGF-β1 into its active form, inducing the
synthesis of collagen in an autocrine fashion (75, 76). Other mechanisms of TGF-β1
activation – such as ROS, mechanical stretch, contraction and even extreme
temperature changes – may also be pivotal to contributing to TGF-β1-induced fibrotic
responses in asthma (Table 1).
10

Differentiation
An increase in the number of structural cells with a contractile-like phenotype
may contribute to increased and sustained AHR in asthma subjects. TGF-β1 promotes
the differentiation of epithelial cells, fibroblasts, and ASM cells in asthma into a more
contractile phenotype through both canonical (77) and non-canonical (78) signaling
pathways. Following airway injury, injured epithelia undergo a process termed epithelialto-mesenchymal transition (EMT). Possibly, the transition of epithelial cells to a
mesenchymal phenotype may play a role in the development of airway remodeling and
increased airway contractility. While several cytokines are implicated in EMT, this
process is largely driven by the Smad-dependent and -independent actions of TGF-β1
(79–81). Additionally, collagen and cadherin – two profibrotic proteins induced by TGFβ1 – have been shown to promote EMT (82, 83). Furthermore, p38 MAPK activation,
oxidative stress, endothelin-1, Wnt signaling, and cytokine signaling modulate TGF-β1induced EMT (79, 80, 84–87).
Evidence demonstrates that TGF-β1 also promotes the differentiation of
fibroblasts into myofibroblasts through a variety of mechanisms (88, 89). Interestingly, it
has been demonstrated that increased substrate stiffness enhances the differentiation of
bronchial fibroblasts to myofibroblasts (90), suggesting the potential of a feed-forward
cycle governing TGF-β1-induced structural changes, differentiation, and airway
contractility.
Proliferation and Apoptosis
The

role of TGF-β1 in structural proliferation is complex and may differ

depending on cell type or the presence of additional growth factors. TGF-β1 induces the
11

proliferation of goblet cells and fibroblasts, but induces apoptosis in epithelial cells (19,
91). In human ASM (HASM) cells, TGF-β1 both induces proliferation (92) and inhibits
mitogen-induced proliferation (93) through different pathways. Additionally, TGF-β1
induces greater proliferation in HASM cells from severe asthma patients as compared
with those from non-severe asthma patients (94), suggesting that TGF-β1’s effects on
structural cell proliferation may depend on disease state.
Studies suggest that TGF-β1-induced proliferation may be attributed to the
stimulation of MAPK phosphorylation (95) and/or ROS production via NOX4 activation
(96). TGF-β1 may also inhibit proliferation by affecting the release of other growth
factors such as VEGF (97), or be mediating store-operated calcium (Ca2+) entry (98).
Furthermore, TGF-β1 may affect proliferation alone or in conjunction with other growth
factors. Evidence also suggests that TGF-β1 can crosstalk with the muscarinic (M2)
receptor to further augment proliferation in HASM (99). TGF-β1-induced proliferation
may also be Ca2+ dependent, as suggested by studies in rat ASM cells (98).
In addition to increasing cell number, TGF-β1 augments HASM cell size in a
process termed hypertrophy. Studies show that preventing TGF-β1 overexpression or
signaling reduces and/or leads to a parallel decline in HASM hypertrophy (100). It is
suggested that TGF-β1 may mediate its effects on HASM hypertrophy through the
activation of NOX4 (92).
In contrast to its effects on proliferation and cell size, TGF-β1 promotes cell death
under certain circumstances. Evidence shows that TGF-β1-induced NOX4 plays a major
role in epithelial cell death - a consequence that may contribute to the development of
pulmonary fibrosis (101). Additionally, TGF-β1 may stimulate apoptosis-mediated
12

pulmonary fibrosis through its interaction with the Bax pathway and stimulation of matrix
metalloproteinases (70). TGF-β1 has also been shown to inhibit apoptosis in fibroblasts
through the activation of phosphoinositide 3-kinase (PI3K)/Akt and p38 MAPK (102–
104).
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TGF-β1 and Airway Disease: Contraction, Cell Shortening, and Cytoskeletal
Motors

HASM cells serve as the pivotal cell regulating bronchomotor tone. HASM
excitation-contraction (E-C) coupling occurs when a contractile agonist binds to its Gprotein-coupled receptor (GPCR) on the HASM cell membrane as shown in Figure 2.
Agonist binding induces the production of diacylglycerol (DAG) and inositol-1,4,5trisphophate (IP3) from phosphatidylinositol 4,5-bisphosphate (PIP2). Following PIP2
cleavage, IP3 enters the cytosol and binds to the inositol trisphosphate receptor (InsP3R)
on the sarcoplasmic reticulum. The subsequent release of Ca2+ into the intracellular
space by the InsP3R and ryanodine receptor channels induces myosin light chain kinase
(MLCK) activation (105, 106). Activated MLCK phosphorylates myosin light chain 20
(MLC), evoking a 10-fold increase in actomyosin ATPase activity and subsequent
contraction (105–107). Additionally, HASM contraction and AHR is mediated by the
actions of Rho kinase (ROCK).
Although studies show an effect of TGF-β1 on HASM contraction, the
mechanisms underlying TGF-β1-induced HASM contraction remain unknown (Figure 2).
Evidence suggests that TGF-β1 affects HASM shortening by Smad-mediated contractile
protein expression and ROS production. Additionally, numerous studies demonstrate a
role for TGF-β1 in ROCK activation (108–111). While the role of TGF-β1 in mediating
classic E-C coupling remains unclear, TGF-β1 modulates Ca2+ homeostasis in a variety
of cell types. TGF-β1 treatment induces an immediate and transient Ca2+ release in
human osteoblasts (112). In human pulmonary fibroblasts, both acute and overnight
TGF-β1 treatment evokes Ca2+ transients (113). In order to further determine the
14

potential role of TGF-β1 in E-C coupling, future studies investigating TGF-β1’s role in
HASM cell Ca2+ mobilization will be essential.

Contractile Protein Expression
TGF-β1 increases contractile protein expression in HASM, fibroblasts, and
myofibroblasts. TGF-β1 induces the expression of SM22, calponin, ∂-SMA, MLCK, and
Ca2+ pathway proteins in HASM cells, subsequently mediating enhancements in cell
stiffness, actin-cytoskeleton reorganization, and contractility (98, 114, 115). Additionally,
mast cell-derived TGF-β1 may modulate the phenotype of HASM cells, promoting their
differentiation into a more contractile phenotype and subsequently enhancing agonistinduced contraction (116).
Smad3 - but not Smad2 - plays a role in TGF-β1-induced contraction of various
cell types. Studies suggest that TGF-β1 induces the contraction of human lung
fibroblasts through a Smad-dependent mechanism (117, 118). TGF-β1 may also
increase contractile protein expression through PI3K. The induction of ∂-SMA, calponin,
and myosin heavy chain in HASM by TGF-β1 decreases following administration of the
PI3K pan-inhibitor LY294002 or the PI3K-delta specific inhibitor IC87114 (119, 120).

RhoA/ROCK Signaling Pathways
Ca2+ sensitization and MLC phosphorylation in ASM E-C coupling occurs in part
by the GPCR-mediated activation of the RhoA/ROCK signaling pathway (Figure 2).
Possibly, TGF-β1 may induce ASM contraction through the activation of RhoA/ROCK
15

signaling pathways. Evidence suggests that induction of the RhoA/ROCK pathway
following TGF-β1 treatment mediates the phosphorylation of MLC (121). In this study,
inhibition of ROCK with the soluble inhibitor Y-27632 - as well as inhibition of RhoA with
the C3 exoenzyme - decreased TGF-β1-induced ROCK activation. Interestingly,
activation of RhoA by TGF-β1 may occur as early as 1-2h and last as long as 6h,
suggesting a mechanism by which TGF-β1 may induce contraction and AHR on both an
acute and chronic level (110, 121).
TGF-β1 may also induce ASM contraction through crosstalk of the TGF-β1 and
GPCR-mediated signaling pathways in HASM as shown in Figure 2. TGF-β1-mediated
induction of ∂-SMA and calponin expression - as well as the induction of ∂-SMA stress
fibers - was increased by treatment with methacholine, a GPCR agonist (99). These
effects occurred through a non-genomic mechanism involving the phosphorylation of
GSK-3β and 4E-binding protein 1, suggesting that TGF-β1 and methacholine may work
together to acutely augment HASM contraction (20).

ROS Production and NOX4
TGF-β1 may induce ASM shortening by inducing the expression of NOX4, the
major ROS-generating enzyme in HASM cells (122). Unlike the majority of NOX
enzymes, NOX4 is a constitutively active enzyme that may be regulated predominantly
by its expression levels (123). Similar to TGF-β1 levels, NOX4 expression is increased in
the ASM and fibroblasts derived from subjects with asthma (124). Interestingly, NOX4
may also regulate TGF-β1 and Smad signaling in a feed-forward manner (63). Studies
suggest that NOX4-mediated ROS production may mediate TGF-β1 signaling or activate
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latent TGF-β1 in an autocrine fashion (125, 126). Additionally, increased cellular ROS
may influence E-C coupling by acting on Ca2+ signaling pathways or modifying the
phosphorylation of kinases in the contractile pathway (127). Indeed, the inhibition of
NOX4 decreases agonist-induced contractility in HASM (124), suggesting a role for
NOX4-mediated ROS in TGF-β1-induced AHR

Synthetic Function
TGF-β1 mediates many of its actions by stimulating the release of additional
growth factors and inflammatory mediators from airway structural cells. In HASM cells,
TGF-β1 stimulates the expression of COX-2 and the release of PGE-2 and IL-8 (128) mediators demonstrated to affect HASM contractile or fibrotic responses (129–131).
Additionally, TGF-β1-induced mediator release from the airway epithelium may affect
contractile or fibrotic function in HASM cells. Studies placing TGF-β1-stimulated airway
epithelial cells in co-culture with HASM cells - or studies that treated HASM cells with
TGF-β1-stimulated epithelial cell culture media – suggest that TGF-β1 induces epithelial
cell mediator release that may further alter HASM function, contractility, or proliferation
(132).

Role of Epithelium in TGF-β1-induced HASM Contraction
Given the proximity of the airway epithelium to HASM, soluble mediators
released by airway epithelial cells may mediate HASM contraction and relaxation.
Following an airway injury or assault, bronchial epithelial cells release various soluble
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mediators, interleukins, arachidonic acid metabolites, and prostaglandins such as
PGF2a, which evoke bronchoconstriction (133, 134). Epithelial cell-derived soluble
mediators – including cytokines, chemokines, TGF-β1, and other growth factors - recruit
inflammatory cells that induce further damage to the airways (135–137). This influx of
cytokines and increased inflammation damages airway epithelium, increasing TGF-β1
and soluble mediator release and potentially inducing airway hypercontractility.
Conversely, airway epithelial cells can also release soluble mediators such as GABA or
nitric oxide that induce relaxation of HASM (138, 139).
Whether airway epithelium-derived soluble mediators directly affect HASM
function remains unclear. Soluble mediators released from airway epithelial cells may be
altered by interaction with the subepithelium before reaching HASM (140). Epithelial cellto-cell contacts, however, may become compromised in the airways of subjects with
asthma, allowing epithelial cell mediators to reach the underlying structural cells. Several
studies show that many adhesion proteins necessary for epithelial cell-to-cell contacts
are downregulated in the airway epithelium of patients with asthma (141–143). Due to
this uncertainty, determining the circumstances under which airway epithelium and
subepithelium modify HASM contraction and relaxation responses will be essential for
future studies investigating the effect of the surrounding milieu on HASM contraction and
AHR.
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Summary

TGF-β1 plays diverse roles in mediating airway structural cell proliferation,
differentiation, and contractile protein expression. These aspects of structural cell
function play a substantial role in the pathology of many airway diseases. In asthma,
TGF-β1 expression is upregulated in airway structural cells and increased in the airway
following immune cell activation. Due to the multiple roles of TGF-β1 in the airway and
occasional conflicting literature on TGF-β1 action, more research is required to elucidate
the role of TGF-β1 in structural airway cells.
As TGF-β1 can substantially affect cellular differentiation and proliferation,
special attention should be paid to normalizing the density, growth conditions, and cell
cycle state of the cells used in future TGF-β1 function experiments. Further
determination of TGF-β1 action in specific structural cell types - as well as development
of methods to specifically target TGF-β1 in these cell types - will be necessary for the
future development of effective TGF-β1 therapeutics that exhibit minimal side effects.
In this dissertation, we hypothesize that TGF-β1 contributes to HASM AHR by
modulating HASM cell shortening and bronchodilator resistance. We begin with the
observation that TGF-β1 augments basal and agonist-induced shortening in HASM cells
and human small airways (Chapter 2). To isolate the mechanism by which this occurs,
we explore TGF-β1’s role in the Ca2+-dependent and Ca2+-independent arms of the
HASM cell excitation-contraction coupling pathway. We next investigated the role of
TGF-β1 in decreasing β2-agonist sensitivity in HASM cells (Chapter 3). We observed
that TGF-β1 decreases β2-agonist-induced relaxation responses in HASM cells and
19

human small airways. To determine the mechanism by which this occurs, we
investigated the effect of TGF-β1 on downstream β2AR signaling. Through this work, we
establish TGF-β1 as a signaling target to decrease AHR and β2-agonist resistance.
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Figure Legends

Figure 1. The tentative role of TGF-β1 signaling in airway remodeling and AHR.
TGF-β1 is synthesized as a latent precursor molecule that is secreted into the
extracellular space or held in the extracellular matrix by integrins. Following activation by
integrins, proteases, and other mechanisms, activated TGF-β1 binds to TBR-I/II. TBR-I
kinase activity induces Smad2/3 phosphorylation, and phosphorylated Smad2/3
associates with Smad4 and translocates to the nucleus to mediate gene expression.
Additionally, studies show that TGF-β1 can signal through numerous Smad–independent
pathways. Both Smad-dependent and –independent pathways may work to affect facets
of airway remodeling and hyperresponsiveness in airway structural cells. Abbreviations:
TGF-β1, transforming growth factor beta 1; ROS, reactive oxygen species; TBR-I/II,
transforming growth factor beta receptor I/II
Figure 2. Potential mechanisms governing TGF-β1-induced HASM contraction.
Agonist binding to a GPCR in ASM induces both a Ca2+-dependent pathway through
Gq/11 activation, and a RhoA/ROCK-mediated Ca2+-sensitization pathway through G12/13
activation. In the Ca2+-dependent pathway, IP3 induces Ca2+ release from the
sarcoplasmic reticulum stores. Increased [Ca2+]i activates Ca2+/CaMKII which activates
MLCK. MLCK phosphorylates MLC20, leading to actin-myosin cross-bridge cycling and
contraction. Additionally, RhoA/ROCK activation can suppress MLCP in the Ca2+sensitization pathway, resulting in increased contractility. Following TGF-β1 binding to
TBR-I and TBR-II, TGF-β1 can signal through Smad-dependent or -independent
signaling pathways that may affect ASM contractile function. Abbreviations: TGF-β1,
transforming growth factor beta 1; HASM, human airway smooth muscle; GPCR, G21

protein-coupled receptor; [Ca2+]i, intracellular calcium; IP3, inositol 1,4,5-trisphosphate;
Ca2+/CaMKII, calcium/calmodulin-dependent kinase II; MLCK, myosin light chain kinase;
ROCK, rho-associated protein kinase; MLC20, 20-kDa myosin light chain 20; MLCP,
myosin light-chain phosphatase; TBR-I/II, TGF-β receptor I/II; ∂-SMA, alpha smooth
muscle actin; SM22-∂, smooth muscle protein 22-alpha; RhoA, ras homolog gene family,
member A
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Latent TGF-ß1

Figure 2
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Table Legends

Table 1. Mechanisms governing TGF-β1 activation. Abbreviations: NOX4; NADPH
Oxidase 4; MMPs, matrix metalloproteinases; M6P, mannose-6-phosphate; IGF2R,
insulin-like growth factor II receptor
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Tables
Table 1

Table 1. Mechanisms governing TGF-ß1 ac<va<on

Ac#va#on Mechanism

Subtype

Reference

NOX4-mediated
Asbestos-generated
CD4+CD25-T cell ac<va<on-generated
Ar<ﬁcially-produced

[90,142–144]
[145]
[117]
[146]

Integrins

∂Vß3
∂Vß5
∂Vß6
∂Vß8

[147,148]
[147,149]
[150,151]
[60]

Proteases

Plasmin
Thrombin/Thrombospondin-1
MMPs

[152,153]
[153–155]
[156–159]

Mechanical stretch
Contrac<on

[160]
[23]

pH

N/A

[152,161]

Temperature

N/A

[161–163]

Co-culture

N/A

[164–167]

Plasmin

N/A

[152,165,168]

Deglycosyla#on

N/A

[169]

M6P/IGF2R

N/A

[170,171]

ROS

Mechanical stretch/contrac#on
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CHAPTER 2: TGF-β1 Evokes Human Airway Smooth Muscle Cell Shortening and
Hyperresponsiveness via Smad3
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Abstract

Transforming growth factor beta 1 (TGF-β1), a cytokine whose levels are elevated in the
airways of patients with asthma, perpetuates airway inflammation and modulates airway
structural cell remodeling. However, the role of TGF-β1 in excessive airway narrowing in
asthma, or airway hyperresponsiveness (AHR), remains unclear. In this study, we set
out to investigate the direct effects of TGF-β1 on human airway smooth muscle (HASM)
cell shortening and hyperresponsiveness. The dynamics of AHR and single-cell
excitation-contraction (E-C) coupling were measured in human precision-cut lung slices
(hPCLS) and in isolated HASM cells using supravital microscopy and magnetic twisting
cytometry (MTC), respectively. In hPCLS, overnight treatment with TGF-β1 significantly
augmented basal and carbachol-induced bronchoconstriction. In isolated HASM cells,
TGF-β1 increased basal and methacholine-induced cytoskeletal stiffness in a dose- and
time-dependent manner. TGF-β1-induced single-cell contraction was corroborated by
concomitant increases in myosin light chain (MLC) and myosin phosphatase target
subunit 1 (MYPT1) phosphorylation levels, which were attenuated by siRNA-mediated
knockdown of Smad3 and pharmacological inhibition of Rho kinase. Strikingly, these
physiologic effects of TGF-β1 occurred through a RhoA-independent mechanism with
little effect on HASM cell [Ca2+]i levels. Together, our data suggest that TGF-β1
enhances HASM E-C coupling pathways to induce HASM cell shortening and
hyperresponsiveness. These findings reveal a potential link between airway injury-repair
responses and bronchial hyperreactivity in asthma, and define TGF-β1 signaling as a
potential target to reduce AHR in asthma.
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Introduction

Asthma, a chronic obstructive airway disease, affects approximately 300 million
individuals worldwide (144). Asthma is characterized by airway inflammation and airway
hyperresponsiveness

(AHR)

to

endogenous

or

exogenous

stimuli

(145).

As

approximately 5-10% of individuals with asthma are refractory to inhaled glucocorticoid
therapy (146, 147), there is an urgent need to identify new therapeutic targets
modulating AHR to reduce asthma-related morbidity.
Transforming growth factor beta-1 (TGF-β1), a pro-fibrotic cytokine elevated in
the airways of patients with asthma, is released following airway injury-repair responses
and may contribute to AHR (148, 149). Canonical TGF-β1 signaling begins when
activated TGF-β1 binds to the serine-threonine kinase TGF-β Type II Receptor (TβR-II).
Following TGF-β1 binding, TβR-II recruits and phosphorylates TGF-β Type I Receptor
(TβR-I) at serine/threonine residues. Activated TβR-I then recruits and phosphorylates
Smad2 and Smad3 (Smad2/3), downstream TGF-β1 transcriptional mediators that
translocate to the nucleus following association with Smad4 (150, 151). TGF-β1 can also
signal through a variety of Smad-independent pathways in various cell types (152).
TGF-β1 enhances a-smooth muscle actin, myosin light chain kinase (MLCK),
and smooth muscle myosin heavy chain contractile protein expression in human airway
smooth muscle (HASM) cells, and promotes the differentiation of airway structural cells
to a more contractile phenotype (90, 149, 153). However, the role of TGF-β1 in HASM
cell excitation-contraction (E-C) coupling and AHR has yet to be defined.
Classic HASM E-C coupling occurs when an agonist binds to a G protein–
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coupled receptor (GPCR) on the HASM cell membrane (Fig. 7). Agonist binding induces
an influx of Ca2+ from the sarcoplasmic reticulum into the intracellular space ([Ca2+]i),
activating Ca2+/calmodulin-dependent kinase II (CamKII). Upon phosphorylation by
CamKII, MLCK evokes myosin light chain (MLC20) phosphorylation and subsequent cell
shortening (105, 106). HASM E-C coupling is also mediated by the sensitivity of the
contractile apparatus to [Ca2+]i. Myosin light chain phosphatase (MLCP) regulates the
relaxation of HASM through the dephosphorylation of MLC20. In addition, Rhoassociated kinase (ROCK) suppresses MLCP activity in a process known as Ca2+sensitization. Upon agonist binding to HASM cells, the small GTPase RhoA activates
ROCK. ROCK suppresses MLCP activity by phosphorylating myosin phosphatase target
subunit 1 (MYPT1), the myosin-binding subunit of MLCP (154). As inactive MLCP can
no longer dephosphorylate MLC20, a given level of Ca2+ induces higher levels of
phosphorylated MLC20 and a subsequent increase in HASM contractility.
TGF-β1 modulates [Ca2+]i levels and ROCK activation in some cell types,
suggesting a potential role for TGF-β1 in HASM cell E-C coupling. TGF-β1 augments
[Ca2+]i release in human pulmonary fibroblasts and human osteoblasts (112, 113).
Furthermore, TGF-β1 activates RhoA/ROCK signaling in human periodontal ligament
cells, rodent fibroblasts, and mammary epithelial cells (108, 149, 155). Using primary
HASM cells and human precision-cut lung slices (hPCLS), we aimed to elucidate the
role of TGF-β1 signaling in HASM cell E-C coupling and AHR.
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Materials and Methods

Human Airway Smooth Muscle (HASM) Cell Culture
Primary HASM cell lines were derived from the trachea of otherwise healthy, aborted
transplant human lung donors from the National Disease Research Interchange (NDRI;
Philadelphia, PA, USA) and International Institute for the Advancement of Medicine
(IIAM; Edison, NJ, USA). HASM cells were isolated and cultured as previously described
(156).
Human Precision-Cut Lung Slices (hPCLS) Preparation and Assays
hPCLS were prepared from NDRI or IIAM human lung donors (157), and
bronchoconstriction assays were conducted as previously described (158). The log of
the half (EC50) and 25% (EC25) maximal effective concentration, and maximal agonistinduced contraction (Emax), was calculated from generated dose-response curves.
Immunoblot Analysis
HASM cells were serum starved for 24 h prior to treatment and collected as previously
described (159). Immunoblots represent findings from individual experiments and are
representative of at least three biological replicates.
Magnetic Twisting Cytometry (MTC)
MTC measures dynamic changes in the cytoskeletal stiffness as a surrogate for agonistinduced force generation at the single-cell level (160). MTC was performed as described
in previous studies (161).
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Small Interfering RNA (siRNA) Transfection
RNA knockdown was performed using a reverse transfection procedure. HASM cells
were trypsinized and resuspended in plain media, then incubated with Hi-Perfect
Transfection Reagent (Qiagen, Hilden, Germany #301705) and siRNA before plating for
a final siRNA concentration of 10 µM.
Intracellular Calcium ([Ca2+]i) Studies
[Ca2+]i was measured using Fluo-8 dye as described previously (159). Following Fluo-8
incubation, images were taken every second for 90 s. Carbachol (10 µM) or histamine (1
µM) was manually added to the chamber after recording 10 frames. HASM cell
fluorescence was normalized to baseline and area under the curve was examined.
TGF-β Ligand and Receptor Transcript Expression
Baseline transcript expression levels were obtained from previously published data
(162). Briefly, primary HASM cells were isolated from five white donors who died of fatal
asthma or from ten donors with no history of chronic illness or medication use.
Construction, sequencing, and data analysis of the total RNA-Seq library was conducted
as previously described (162). For each sample, kallisto (v0.42.3) was used to quantify
hg38 transcripts and Sleuth was used for differential expression analysis (163, 164).
Statistical Analysis
GraphPad Prism software (La Jolla, CA, USA) was used to determine significance
evaluated at a p-value of < 0.05 using a Student's unpaired t-test or multiple t-tests with
Holm-Sidak correction unless otherwise noted. Data is represented as mean+/-SEM,
with a minimum of three biological replicates per condition.
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Materials
Compounds were purchased from Sigma Aldrich (St. Louis, MO, USA) [carbachol,
perchloric acid], Enzo Life Sciences (Farmingdale, NY, USA) [Y-27632], and R&D
Systems (Minneapolis, MN, USA) [TGF-β1, SB-431542]. Antibodies were purchased
from Cell Signaling Technologies (Danvers, MA, USA) [pMLC(3674S), pMYPT1s507(3040S),

GAPDH(2118S),

RhoA(2117S)],

Abcam

(Cambridge,

MA,

USA)

[Smad3(ab28379), Smad2(ab71109), pSmad3(ab52903)], EMT Millipore (Billerica, MA,
USA) [MLC(MABT180)], BD Biosciences (San Jose, CA, USA) [total MYPT1(612165)],
and Santa Cruz Biotechnology (Dallas, TX, USA) [Smad4(sc-7966)]. siRNA was
purchased from Thermofisher Scientific (Waltham, MA, USA) [Smad3(VHS41114)],
Dharmacon

(Lafayette,

CO,

USA)

[Smad2(L-003561-00)],

[RhoA(S102654211).
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and

Qiagen

Results

TGF-β1 augments basal and agonist-mediated hPCLS bronchoconstriction
To determine the physiological effects of TGF-β1 on the airway, hPCLS airway
lumen area was measured prior to and after treatment with TGF-β1 as shown in Figure
1. Overnight TGF-β1 treatment significantly decreased basal hPCLS luminal airway area
(Fig. 1A). To investigate the role of TGF-β1 in mediating AHR, hPCLS were treated with
TGF-β1 or vehicle overnight and then stimulated with carbachol in a dose-dependent
manner (Fig. 1B). As these slices are derived from donors of a heterogeneous
population, we expectedly observe variations in degree of response to contractile
agonists. To most accurately determine the effect of TGF-β1 on carbachol-induced
bronchoconstriction, hPCLS were subjected to a carbachol contractile test prior to
contractile studies. Following washes and incubation to return the slice to baseline
luminal diameter, only hPCLS exhibiting bronchoconstriction over 40% were used for
subsequent assays. As shown in Fig. 1B, TGF-β1-pretreated hPCLS exhibited 25%
airway narrowing at a lower concentration of carbachol as compared to control (log EC25
= -0.7867 ±0.088 versus log EC25 = -1.406 ±0.085), along with a significant increase in
the maximal contraction (Emax).

TGF-β1 augments basal and agonist-induced cell stiffening and [Ca2+]i in HASM cells
The direct effect of TGF-β1 on isolated HASM cell shortening was determined
using magnetic twisting cytometry (MTC). TGF-β1 significantly increased basal HASM
cell stiffness in a dose- and time-dependent manner, showing significantly increased
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contractile responses as early as 1 h post-exposure (Fig 2A). To further characterize the
effects of TGF-β1 on the HASM cell contractile apparatus, methacholine-and histamineinduced cell stiffness was measured in HASM cells pretreated with TGF-β1 overnight
(Fig 2C). TGF-β1 significantly enhanced HASM cell stiffness to both agonists.
Furthermore, inhibition of TβR-I kinase activity with SB-431542 - a TβR-I antagonist significantly decreased the enhancement of basal and agonist-mediated HASM cell
stiffness by TGF-β1 (Fig. 2B, 2C).
To determine the role of TGF-β1 in mediating HASM cell [Ca2+]i, Fluo-8 was used
to measure [Ca2+]i following treatment of HASM cells with TGF-β1 (Fig. 2D). Acute
stimulation with TGF-β1 alone showed little effect on [Ca2+]i transients over that of
vehicle control (Fig. E1). TGF-β1-pretreated HASM cells, however, showed significantly
increased area under the curve (AUC) following carbachol stimulation as compared to
that from carbachol alone (Fig. 2D).

TGF-β1 augments basal and agonist-induced HASM MLC20 phosphorylation
We next treated HASM cells with TGF-β1 in the presence or absence of
contractile agonists and investigated the phosphorylation of MLC20 - a necessary
signaling event in agonist-induced HASM contraction (Fig 3). TGF-β1 increased MLC20
phosphorylation

in

a

time-dependent

manner,

significantly

sustaining

MLC20

phosphorylation for up to 72 h post exposure (Fig. 3A). Additionally, TGF-β1 increased
basal MLC20 phosphorylation and significantly augmented MLC20 phosphorylation to
both carbachol and histamine (Fig. 3B). TβR-I kinase activity inhibition significantly
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reduced TGF-β1-induced MLC phosphorylation and HASM hyperresponsiveness to both
agonists (Fig. 3C).

Rho-Associated Kinase Inhibition Prevents MLC20 Phosphorylation by TGF-β1
In addition to increases in [Ca2+]i, HASM E-C coupling is also mediated by the
sensitivity of the contractile apparatus to Ca2+. To determine the role of ROCK activation
in TGF-β1-mediated HASM cell shortening, we investigated the phosphorylation of
MYPT1 as a surrogate for ROCK activation in TGF-β1 treated HASM cells (Fig. 4). TGFβ1 significantly enhanced basal and carbachol-induced MYPT1 phosphorylation in
treated HASM cells (Fig. 4A).
To

determine

the

necessity

of

ROCK

in

TGF-β1-induced

MLC20

phosphorylation, we investigated TGF-β1-induced MLC20 phosphorylation in HASM
cells pretreated with the ROCK1/2 inhibitor Y-27632 (Fig. 4B). ROCK1/2 inhibition
significantly decreased basal and agonist-induced MLC20 phosphorylation by TGF-β1
as compared to vehicle control. Furthermore, pretreatment with Y-27632 decreased
augmentation of basal and agonist-induced MYPT1 phosphorylation by TGF-β1.
RhoA activation acts upstream from ROCK activation in the HASM cell Ca2+sensitization pathway (165, 166). To determine the contribution of RhoA to TGF-β1induced MLC phosphorylation, HASM cells were transfected with siRNA targeting the
small GTPase RhoA and treated with TGF-β1 overnight in the presence or absence of
carbachol (Fig. 4C). RhoA knockdown had little effect on the augmentation of basal and
agonist-induced MLC20 phosphorylation by TGF-β1 in HASM cells.
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Smad3 knockdown decreases TGF-β1-induced MLC20 phosphorylation and ROCK
activation
Smad2/3 activation and phosphorylation play a major role in the canonical TGFβ1 signaling pathway. To determine the role of canonical TGF-β1 signaling in TGF-β1induced HASM cell shortening, we transfected HASM cells with siRNA against Smad3 or
Smad2 prior to TGF-β1 treatment and agonist stimulation (Fig. 5). Smad3 knockdown
significantly decreased the augmentation of basal and agonist-induced MLC20 and
MYPT1 phosphorylation by TGF-β1, as well as carbachol-induced MLC phosphorylation,
in HASM cells (Fig. 5A). Conversely, Smad2 knockdown had little effect on TGF-β1induced MLC20 or MYPT1 phosphorylation (Fig. 5B). While Smad4 knockdown also
tended to decrease TGF-β1-induced MLC phosphorylation, the results were not
significant relative to diluent control (Fig. E2).

No significant differences in TGF-β family ligand and receptor gene expression between
non-asthma and fatal asthma donor-derived HASM cells
We and others have demonstrated that HASM cells derived from donors with
fatal asthma display distinct phenotypic differences compared to those derived from nonasthma donors (167–169). To determine whether the observed differences may be due
to differential expression of TGF-β signaling pathways, we used RNA-Seq to measure
TGF-β family ligand and receptor transcript expression in HASM cells derived from nonasthma and fatal asthma donors (Fig. 6, Table E1). We observed no statistically
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significant differences between TGF-β1, -2, or -3, ligand or receptor transcript
expression in HASM cells derived from non-asthma versus fatal asthma donors.
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Discussion

Severe and persistent asthma is a disease characterized by a repetitive cycle of
airway injury and repair. Studies suggest that repeated airway injury-repair leads to
increased airway resistance and airway hyperresponsiveness (149, 170). However, the
mechanisms mediating airway hyperresponsiveness have yet to be fully understood. Our
findings suggest a unique role for TGF-β1 in mediating airway narrowing and
augmenting agonist-induced shortening. To our knowledge, this is the first report
demonstrating

that

TGF-β1

directly

modulates

HASM

cell

shortening

and

hyperresponsiveness in asthma.
Several cytokines have been previously established as mediators of AHR in
asthma (171). The role for TGF-β1 in AHR, however, has yet to be defined. In this study,
we

demonstrate

that

TGF-β1

augments

basal

and

agonist-induced

hPCLS

bronchoconstriction, HASM cell stiffness, and MLC20 phosphorylation, suggesting a
novel role for TGF-β1 in asthmatic airway obstruction through the mediation of HASM
contraction (Fig. 1, 2A-C, 3B). Additionally, TGF-β1-induced HASM cell contractility is
both time and dose-dependent (Fig. 2A, 3A), peaking following overnight treatment and
sustained for up to 72 h post-exposure (Fig. 3A). Together, these results suggest a role
for TGF-β1 in mediating HASM contraction and AHR in asthma.
HASM contraction is mediated by E-C coupling, a process in which downstream
signaling mediates [Ca2+]i levels and ROCK activation. Interestingly, we show that TGFβ1 augments agonist-induced HASM cell shortening to two agonists that signal through
different GPCRs (Fig. 2C, 3B). Thus, we hypothesized that TGF-β1’s effects on HASM
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shortening and hyperresponsiveness occur downstream of the receptor level through the
modulation of [Ca2+]i and/or ROCK activation.
As a contractile agonist, TGF-β1 had little effect on HASM cell [Ca2+]i transients
over that of vehicle control (Fig. E1). Overnight TGF-β1 treatment, however, enhanced
carbachol-induced [Ca2+]i levels (Fig. 2D). Thus, our data suggests that TGF-β1-induced
[Ca2+]i augmentation may play a modest role in mediating TGF-β1-induced HASM cell
shortening and hyperresponsiveness.
In addition to the elevation of HASM cell [Ca2+]i, HASM E-C coupling is mediated
by the activation of RhoA/ROCK signaling. Through the phosphorylation of MYPT1, we
demonstrate that overnight TGF-β1 treatment augments basal ROCK activation in
HASM cells (Fig. 4A). Additionally, we demonstrate for the first time that TGF-β1
augments agonist-induced HASM cell MLC phosphorylation through ROCK activation
(Fig. 4B), suggesting the necessity of ROCK for TGF-β1-induced HASM cell
hyperresponsiveness. ROCK is a known downstream effector of RhoA, and our lab has
previously established a role for RhoA in the agonist-induced Ca2+-sensitization pathway
(166, 172). Surprisingly, RhoA knockdown has little effect on TGF-β1-induced MYPT1
and MLC20 phosphorylation (Fig. 4C). While the pathways by which TGF-β1 bypasses
RhoA to activate ROCK in HASM cells remain unclear (Fig. 7), it is plausible that TGFβ1 augments HASM cell contraction by enhancing other Rho-family small GTPases that
modulate ROCK activation and MLC20 phosphorylation upstream. Rac1 and Cdc42 are
two such small GTPases that have a demonstrated role in mediating both HASM cell
actin polymerization and the contraction of airway smooth muscle in various species
(173, 174). TGF-β1 may also enhance the expression of CPI-17, ROCK, or other
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downstream proteins in the HASM E-C coupling pathway, serving to prime the cell for
augmented contractile responses to agonists (175).
Activation of Smad2/3 is the canonical TGF-β1 signaling pathway in multiple cell
types. While Smad2 and Smad3 are similar in structure and function, literature suggests
that the two proteins serve different functions in the cell (176, 177). In our study, Smad3
knockdown

significantly

reduced

TGF-β1-induced

HASM

cell

shortening

and

hyperresponsiveness (Fig. 5A). Interestingly, Smad3 knockdown also significantly
decreased carbachol-induced HASM cell shortening. As the cooperation between TGFβ1 and muscarinic pathways has been previously described, it is plausible that Smad3
inhibition may negatively regulate muscarinic responses (20). Notably, Smad2
knockdown alone exhibited little effect on TGF-β1 or carbachol-induced HASM cell
shortening (Fig. 5B). Additionally, knockdown of Smad4–an important component in
Smad2/3 nuclear translocation–showed little reduction in TGF-β1 induced HASM cell
shortening (Fig. E2). These data are in accordance with previous findings in fibroblasts
that demonstrate Smad3 as a pivotal player in TGF-β1-induced contraction (117, 178).
Our study is the first, however, to suggest the necessity of Smad3 for TGF-β1-induced
contraction and hyperresponsiveness in HASM cells (Fig. 5A). Furthermore, as TGFβ1’s effects occur through a pathway that is ROCK-dependent, but RhoA-independent,
the precise mechanisms linking TGF-β1 and Smad3 to ROCK activation remain an
enigma (Fig. 7).
In this study, we did not examine the effects of TGF-β1 on the expression of asmooth muscle actin, smooth muscle myosin heavy chain, MLCK, or other contractile
proteins. It is plausible that enhanced expression of these proteins may modulate TGFβ1’s effects on HASM cell hyperresponsiveness. However, given the significant
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enhancement of MLC phosphorylation and HASM cell stiffness at time points as short as
1 h (Fig. 2A, 3A), we posit that changes in contractile protein expression cannot fully
explain the effects of TGF-β1 and Smad3 on basal and agonist-induced HASM cell
shortening. Taken together, these data suggest a novel role for TGF-β1 and Smad3 in
HASM cell E-C coupling and hyperresponsiveness.
Infiltrating eosinophils are a major source of TGF-β1 in the asthmatic airway (48,
49). Additionally, most airway structural cells produce some levels of TGF-β1 (45, 46).
TGF-β1 protein levels are elevated in the bronchial lavage and epithelial lining fluid of
patients with asthma, and TGF-β1 gene expression is increased in bronchial biopsies
isolated from subjects with severe and moderate asthma as compared with biopsies
from non-asthma subjects (17, 45, 48, 179). In HASM cells, we observed little difference
in TGF-β ligand and receptor gene expression levels between non-asthma and fatal
asthma donors (Fig. 6). However, it is plausible that HASM cell TGF-β1 signaling in
asthma increases following increased production of TGF-β1 from alternative airway cell
types, modulation of HASM cell TGF-β1 protein production or degradation, increased
HASM cell TβR-I/II activation, or increased activation of TGF-β1 on the HASM cell
surface. Airway injury, increased ROS generation, and HASM contraction alone are
demonstrated to induce TGF-β1 activation, further reinforcing the potential important role
of TGF-β1 in modulating airway function (22, 149). Thus, AHR may be closely linked to
the airway injury-repair response that follows repeated asthma exacerbations. TGF-β1’s
prolonged effects on HASM shortening also indicate that elevation of TGF-β1 following
airway injury may increase patient susceptibility to sustained airway obstruction.
Therefore, our study establishes TGF-β1 as a potential link between airway injury and
hyperresponsiveness in asthma. Furthermore, our data suggest TGF-β1 or its signaling
42

pathways may serve as an important therapeutic target for reducing AHR in asthma
patients insensitive to current therapies.
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Figure Legends

Figure 1. Airway narrowing in TGF-β1-treated human precision-cut lung slices
(hPCLS). A) Top: Images were taken both before and after 18 h TGF-β1 exposure in
one hPCLS. Bottom: Increased luminal airway narrowing in TGF-β1 (100 ng/mL, 18 h)
and vehicle control-treated hPCLS (n=9 donors). B) Increased carbachol (Cch)-induced
luminal airway narrowing in TGF-β1 (100 ng/mL, 18 h) and vehicle-treated hPCLS (n=9
donors). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001

Figure 2. Agonist-induced HASM cell [Ca2+]i and contractile responses of isolated
HASM cells. A) TGF-β1 (10-100 ng/mL) treatment increases basal stiffness of isolated
HASM cells (n=221-477 individual cells). B) SB-431542 (10 µM, 1 h pretreatment)
decreases TGF-β1 (10 ng/mL, 18 h)-induced augmentation of basal HASM cell stiffness
(n=187-292). C) SB-431542 (10 µM, 1 h pretreatment) decreases TGF-β1 (10 ng/mL,
18 h)-induced augmentation of Cch (n=552-818) and Hist (n=205-292 individual cells)induced HASM cell stiffness. All MTC data represented as geometric mean (95% CI).
MTC statistical analysis was performed using one-way ANOVA with Tukey post-hoc test.
D) TGF-β1 (10 ng/mL, 18 h) treatment augments Cch-induced [Ca2+]i in isolated HASM
cells.) [Ca2+]i in Cch-stimulated (10 μM) HASM cells following overnight TGF-β1
pretreatment. Three donors; two replicates per condition. *P < 0.05; **P < 0.01; ***P <
0.001; ****P < 0.0001
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Figure 3. MLC20 phosphorylation in TGF-β1-treated HASM cells. A) TGF-β1 (10
ng/mL) induces time-dependent MLC20 phosphorylation (pMLC) in HASM cells (n=3 +/SEM). B) TGF-β1 (10 ng/mL) pretreatment for 18 h augments Cch (10 μM, 10 min) and
histamine (Hist)-induced (1 μM, 10 min) MLC20 phosphorylation (n=5; *P<0.05, ****P <
0.0001) C) Inhibition of TβR-I signaling decreases TGF-β1-induced pMLC. For these
studies, HASM cells were stimulated with TGF-β1 for a total of 18 h. Following 1 h prior
to collection, HASM cells were treated with the ALK5 inhibitor SB-431542 (5 µM). After 1
h, HASM cells were stimulated acutely with vehicle, Cch (10 µM), or Hist (1 µM), lysed
with RIPA, and subjected to immunoblot (n=5 +/- SEM).

Figure 4. Effect of Rho kinase (ROCK) inhibition on TGF-β1-induced MLC20
phosphorylation and hyperresponsiveness in HASM cells. A) HASM cells were
treated with TGF-β1 (10 ng/mL) for 18 h then stimulated with Cch (10 µM) or Hist (1 µM)
for 10 min (n=5 +/- SEM). B) HASM cells were pre-treated with the ROCK inhibitor Y27632 for 15 minutes. HASM cells were then treated with TGF-β1 (10 ng/mL) for 18 h
and stimulated with Cch or Hist (n=8 +/-SEM, n=4 +/-SEM). pMYPT1/MYPT1 Vehicle
versus Y-27632 immunoblots show two different experiments representative of multiple
donor observations. pMLC/MLC Vehicle versus Y-27632 immunoblots show one
representative immunoblot from multiple donor observations. C) HASM cells were
transfected with siRNA targeted against RhoA or a non-targeting (NT) siRNA pool, then
treated with TGF-β1 (10 ng/mL, 18 h) and stimulated with Cch (20 µM, 10 min) (n=3 +/SEM).
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Figure 5. Effect of Smad knockdown on TGF-β1-induced MLC20 phosphorylation
and hyperresponsiveness in HASM cells. HASM cells were transfected with siRNA
against A) Smad3 (n=4-6 +/- SEM) or B) Smad2 (n=3 +/-SEM), pretreated with TGF-β1
(10 ng/mL) or vehicle control for 18 h then stimulated with Cch (20 µM, 10 min).
Following treatment, HASM cells were lysed with RIPA and subject to immunoblot.

Figure 6. TGF-β ligand and receptor basal gene expression in HASM cells derived
from non-asthma (NA) versus fatal asthma (FA) donors. The mRNA expression of
TGF-β A) family ligands and B) receptors were assessed by RNA-Seq in non-asthma
(n=10) and fatal asthma (n=5) donor-derived HASM cells. Shown are the transcripts with
highest expression levels, expressed as transcripts per million, for each gene.

Figure 7. Proposed role of TGF-β1 signaling in HASM cell shortening and
hyperresponsiveness. Following activated TGF-β1 binding to TβR-I/II, TβR-I kinase
activity induces the phosphorylation of Smad2/3. Following association with Smad4, the
phosphorylated Smad2/3 complex translocates to the nucleus to mediate gene
expression. Through a Smad3-dependent pathway, TGF-β1 augments HASM cell MLC
phosphorylation and hyperresponsiveness to multiple agonists. Additionally, TGF-β1
exerts these effects through a ROCK-dependent, RhoA-independent pathway. However,
further details of the mechanism by which Smad3 may induce ROCK, MLC
phosphorylation, and hyperresponsiveness in HASM cells remains unclear. The dotted
line represents potential mechanisms regulating TGF-β1-induced HASM cell shortening
and hyperresponsiveness. Figure modified from previously published image (149).
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Abbreviations: HASM, human airway smooth muscle; GPCR, G-protein-coupled
receptor; TGF-β1, transforming growth factor beta 1; TβR-I/II, TGF-β receptor I/II; SR;
sarcoplasmic reticulum; Ca2+, intracellular calcium; Ca2+/CaMKII, calcium/calmodulindependent kinase II; ROCK, rho-associated protein kinase; MLCP, myosin light-chain
phosphatase; MLCK, myosin light chain kinase; MLC20, 20-kDa myosin light chain 20
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Supplemental Figure Legends

Figure E1. Time-dependent effects of TGF-β1 on HASM cell stiffness. A) Cell
stiffening response to acute stimulation with 10 ng/ml TGF-β1 (N=148-209 individual
cells). B) TGF-β1 (10-100 ng/mL) increases basal tone of isolated HASM cells in a timedependent manner (N=202-389 individual cells) *P< 0.05

Figure E2. Time-dependent effects of TGF-β1 on HASM cell [Ca2+]i transients.
HASM cell [Ca2+]i transients in response to acute stimulation with 10 ng/ml TGF-β1.
Three donors; two replicates per condition (N=3).
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Supplemental Figures

Supplemental Figure 1
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Supplemental Figure 2
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Supplemental Table Legends

Table E1. HASM cell donor characteristics for RNA-Seq gene expression studies.
No significant differences in age, sex, or BMI between non-asthma and fatal asthmaderived donors were found. For fatal asthma donors, cause of death was ruled as
“asthma attack/anoxia” or a significant asthma event by a medical examiner. Presented
table results modified from previously published data (162).
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Supplemental Tables

Supplemental Table 1

Gender

Age

BMI

Cause of Death

Non-Asthma
(N=10)

Fatal Asthma
(N=5)

M

6

2

F

4

3

Mean (SD)

33.1 (15.2)

31.2 (20.1)

[Range]

[17, 52]

[9, 59]

Mean (SD)

27.4 (6.5)

27.4 (6.5)

[Range]

[21.5, 40.5]

[17.9, 34.5]

Head Trauma

4

-

Anoxia

3

-

CVA*

2

-

AVM Rupture †

1

-

*Cerebrovascular accident †Arteriovenous malformation
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CHAPTER 3: TGF-β1 Decreases β2-Agonist-Induced Relaxation in Human Airway
Smooth Muscle

C.A. Ojiaku1,2, J.K. Williams3, E. Chung2, V. Parikh2, A. Schwab2, A. Fuentes2, M.
Corpuz5, V. Lui4, S. Paek4, N.M. Bexiga4, K. Ahn7, R.S. Ostrom5, S.S. An4,6, and R.A.
Panettieri, Jr.2

1

Department of Systems Pharmacology and Translational Therapeutics, Perelman
School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;
2
Rutgers Institute for Translational Medicine and Science, Child Health Institute, Rutgers
University, New Brunswick, New Jersey.
3
Drexel University, Philadelphia, PA.
4
Department of Environmental Health and Engineering, Johns Hopkins Bloomberg
School of Public Health, Baltimore, Maryland, USA.
5
Department of Biomedical and Pharmaceutical Sciences, Chapman University School
of Pharmacy, Irvine, California.
6
Department of Chemical and Biomolecular Engineering, the Johns Hopkins University,
Baltimore, Maryland, USA.
7
National Institute of Mental Health, Bethesda,MD, USA

This chapter was adapted from work submitted to the American Journal of Respiratory
Cell and Molecular Biology, October 2018.

60

Abstract

Helper T effector cytokines implicated in asthma modulate the contractility of human
airway smooth muscle (HASM) cells. We have reported recently that a profibrotic
cytokine, transforming growth factor beta 1 (TGF-β1), induces HASM cell shortening and
airway hyper-responsiveness (AHR). Here we assessed whether TGF-β1 affects the
ability of HASM cells to relax in response to β2-agonists, a mainstay treatment for AHR
in asthma. Overnight TGF-β1 treatment significantly impaired isoproterenol (ISO)induced relaxation of carbachol-stimulated isolated HASM cells. This single-cell
mechanical hypo-responsiveness to ISO was associated with sustained increases in
myosin light chain (MLC) phosphorylation. In TGF-β1 treated HASM cells, ISO evoked
markedly lower levels of intracellular cAMP. These attenuated cAMP levels were, in turn,
restored with pharmacological and siRNA inhibition of PDE4 and Smad3, respectively.
Most strikingly, TGF-β1 selectively induced PDE4D gene expression in HASM cells in a
Smad2/3-dependent manner. Together these data suggest that TGF-β1 decreases
HASM cell β2-agonist relaxation responses by modulating intracellular cAMP levels via a
Smad2/3 and PDE4D-dependent mechanism. Our findings further define the
mechanisms underlying β2-agonist hypo-responsiveness in asthma, and suggest TGFβ1 as a potential therapeutic target to decrease asthma exacerbations in severe and
treatment-resistant asthma.
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Introduction

β2-agonist bronchodilators are a mainstay therapeutic used for acute and longterm control of asthma exacerbations. However, patients with severe asthma often
respond poorly to β2-agonists, and increasing evidence demonstrates that frequent β2agonist use induces resistance and deterioration of asthma control (25, 26). Therefore,
understanding the mechanisms mediating β2-agonist resistance is important for
decreasing asthma-related morbidity and mortality.
Evidence suggests a link exists between β2-adrenergic receptor (β2AR) hyporesponsiveness and airway hyper-responsiveness (AHR), where increased levels of
bronchoconstriction

can

decrease

bronchodilator

responsiveness

(26,

180).

Unsurprisingly, several cytokines modulate hyper-responsiveness and β2-agonist
resistance in human airway smooth muscle (HASM), the main regulator of bronchomotor
tone (171, 181). We have previously reported that transforming growth factor β1 (TGFβ1)–a pro-fibrotic cytokine elevated in the airways of patients with asthma–augments
agonist-induced contractile responses in HASM via a Smad3-dependent pathway (5, 6).
However, the role of TGF-β1 in modulating β2-agonist-induced relaxation responses in
HASM remains unknown.
β2-agonists induce airway relaxation by binding to β2-adrenergic G-protein
coupled receptors (GPCRs) on HASM cells, stimulating adenylyl cyclase (AC) enzyme
activity (182). Adenylyl cyclase activation by the β2AR Gs alpha subunit elevates
intracellular cyclic adenosine monophosphate (cAMP) levels, and increased cAMP leads
to subsequent HASM cell relaxation by antagonizing HASM cell contractile pathways.
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HASM cell relaxation responses are also regulated by the action of prostaglandin E2
(PGE2), an arachidonic acid-derived mediator that exerts its effects via prostanoid EP
receptors from the GPCR family (183, 184). Stimulation of the Gs-coupled EP2 and EP4
receptor subtypes elevates intracellular cAMP levels via activation of adenylyl cyclase,
leading to PGE2-induced relaxant effects in HASM (185).
Intracellular cAMP levels in HASM cells are regulated by the balance between
adenylyl cyclase activation and cAMP-hydrolyzing phosphodiesterase (PDE) activity.
While HASM cells express multiple PDE isoforms (186), functional studies have
established PDE3 and PDE4 as the major cAMP hydrolyzing enzymes (187–189).
PDE4, in particular, plays a pivotal role in HASM cell cAMP degradation and is more
widely studied as a therapeutic target in airway disease (190, 191). Of the four PDE4
encoding genes (192), evidence supports a critical role for PDE4D in mediating HASM
cell contractile and relaxation responses (168, 193–195). Notably, increased PDE4D
activity and expression is associated with decreased β2-agonist-induced cAMP
generation in HASM from subjects with asthma (168). Mice deficient in PDE4D also
exhibit a loss of responsiveness to cholinergic stimulation (10), suggesting the
therapeutic potential of PDE4D inhibitors in asthma.
Previous studies investigating the role of TGF-β1 in decreased β2AR responses
have been predominantly biochemical in nature and largely limited to human tracheal
smooth muscle cells and human lung embryonic fibroblasts (196, 197). As these studies
were conducted in the presence of PDE inhibitors, neither study assessed the potential
of TGF-β1 to modulate downstream components of the cAMP signaling pathway via
PDE4. Therefore, we aimed to elucidate the mechanisms by which TGF-β1 modulates
β2-agonist-induced relaxation responses in HASM cells.
63

Methods

Human Airway Smooth Muscle (HASM) Cell Culture
Human lungs from otherwise healthy, aborted transplant donors were received from the
International Institute for the Advancement of Medicine (IIAM; Edison, NJ, USA) and the
National Disease Research Interchange (NDRI; Philadelphia, PA, USA). HASM cells
were isolated from the trachea and cultured as previously described (156).

Immunoblot Analysis
Confluent HASM cells were serum starved overnight prior to treatment and collected as
previously described (159). Immunoblots are single experiments representative of at
least three biological replicates.

Magnetic Twisting Cytometry (MTC)
HASM cells were pre-contracted to carbachol in the presence or absence of
pharmacological inhibitors. MTC was used to assess dynamic regulation of individual
HASM cell contractile responses following isoproterenol stimulation (198).
measurements were performed as described in previous studies (160, 161).

Small Interfering RNA (siRNA) Transfection
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MTC

In vitro siRNA knockdown was performed using a reverse transfection procedure as
previously described (199). Briefly, trypsinized HASM cells were resuspended in plain
media containing Hi-Perfect Transfection Reagent (Qiagen, Hilden, Germany #301705)
and siRNA. HASM cells were seeded onto cell culture plates for a final siRNA
concentration of 10 µM. Cells were collected 72 h after transfection and serum-starved
24 h prior to treatment.

Measurement of Cyclic AMP Levels
HASM cells at 80% confluency were serum starved overnight. Following stimulation,
cells were lysed and cAMP levels were measured using the Applied Biosystems cAMPScreen® ELISA system according to manufacturer protocol.

Quantitation of Phosphodiesterase (PDE) Gene Expression
RNA was isolated and purified from HASM cells using the RNeasy Mini Kit (Qiagen
Sciences, Inc., Germantown, MD, USA). cDNA was generated from RNA using
SuperScript™ IV First-Strand Synthesis System (Thermo Fisher Scientific, Waltham,
MA, USA). PDE gene expression was determined in HASM cells as previously described
(200).

Statistical Analysis
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Unless otherwise stated, statistical analysis was conducted using GraphPad Prism
software (La Jolla, CA, USA), with significance evaluated at a p-value of < 0.05.
Significance was determined using Student's unpaired t-tests or multiple t-tests with
Holm-Sidak correction. Data is reported as mean+/-SEM with three or more biological
replicates per condition. For MTC experiments involving multiple lung donor cell
responses, statistical analysis was conducted using mixed effect models using SAS
V.9.2 (SAS Institute Inc., Cary, NC) (201).

Materials
Compounds were purchased from Sigma Aldrich (St. Louis, MO, USA) [isoproterenol,
prostaglandin E2, carbachol, perchloric acid], Selleck Chemicals (Houston, TX, USA)
[roflumilast], Cayman Chemicals (Ann Arbor, MI, USA) [3-isobutyl-1-methylxanthine
(IBMX)], and R&D Systems (Minneapolis, MN, USA) [TGF-β1, SB-431542]. Immunoblot
antibodies were purchased from Cell Signaling Technologies (Danvers, MA, USA)
[pMLC(3674S)] and EMT Millipore (Billerica, MA, USA) [MLC(MABT180)]. siRNA was
purchased from Thermofisher Scientific (Waltham, MA, USA) [Smad3(VHS41114)] and
Dharmacon (Lafayette, CO, USA) [Smad2(L-003561-00), Non-targeting Pool(D-00181010-05)].
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Results

TGF-β1 Decreases β2-Agonist-Induced Relaxation in HASM Cells
To determine the extent to which TGF-β1 mediates resistance to β2AR-induced
relaxation in HASM cells, TGF-β1-pretreated HASM cells were stimulated acutely with
the β2-agonist isoproterenol (ISO) (Fig. 1). Single-cell relaxation responses were
determined using magnetic twisting cytometry (MTC), a technique that measures
changes in cell stiffness as a surrogate for agonist-induced force generation (198). TGFβ1- or vehicle-pretreated cells were pre-contracted to carbachol and stimulated acutely
with ISO. TGF-β1 significantly impaired ISO-induced single-cell relaxation in basal and
carbachol-stimulated HASM cells as compared to vehicle control (Fig. 1A). To further
confirm TGF-β1’s effects on HASM cell contractile responses, we investigated the
phosphorylation of MLC–an essential component of agonist-induced HASM cell
contraction–following overnight TGF-β1 treatment. TGF-β1 augmented basal and
agonist-induced MLC phosphorylation in a similar manner to previously published
literature (202). Following stimulation with ISO, MLC phosphorylation in TGF-β1-treated
HASM cells remained significantly higher than that of vehicle control (Fig. 1B,
Supplemental Fig. 1). Notably, the addition of the contractile agonist carbachol to TGFβ1- and ISO-treated HASM cells significantly increased MLC phosphorylation to levels
above that in TGF-β1 and ISO-treated HASM cells.
The role of TGF-β1 in mediating airway hyporesponsiveness to β2-agonistinduced bronchodilation was measured ex vivo using hPCLS. Pre-contracted slices were
subject to increasing concentrations of formoterol, and bronchodilation was measured by
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investigating alterations in hPCLS airway lumen area. TGF-β1 pre-treated hPCLS
modestly decreased β2-agonist-induced relaxation relative to vehicle control in precontracted slices (Supplemental Fig. 2).

TGF-β1 Blunts Agonist-Induced cAMP Levels
To elucidate the mechanism by which TGF-β1 reduces HASM cell relaxation
responses, cAMP levels were measured in TGF-β1-treated HASM cells. In TGF-β1
treated cells, ISO- and PGE2-induced cAMP levels were decreased versus that of the
respective controls (Fig. 2A). TGF-β1 treatment also increased forskolin-stimulated
cAMP levels (33 ± 19.5%) in HASM cells, although this increase did not reach
significance (Fig. 2B).

PDE Inhibition Rescues ISO-Stimulated Responses in TGF-β1-Treated HASM Cells
Intracellular cAMP levels are primarily reduced via hydrolysis–an effect mediated
by the action of PDEs in HASM cells (203). To determine whether TGF-β1 mediates β2agonist hypo-responsiveness by modulating PDE-mediated cAMP hydrolysis, MLC
phosphorylation and cAMP levels were measured in TGF-β1- and ISO-treated HASM
cells in the presence or absence of the pan-PDE inhibitor IBMX (Fig. 3, Supplemental
Fig. 3A).
MLC phosphorylation in HASM cells was increased following TGF-β1 treatment,
and levels remained higher than vehicle control following ISO stimulation (Fig. 3A,
bottom left). Treatment with IBMX, however, reduced MLC phosphorylation in TGF-β168

pre-treated, ISO-stimulated HASM cells to a level similar to that of vehicle control (Fig.
3A, bottom left). In basal and ISO-stimulated HASM cells, MLC phosphorylation levels
were increased in TGF-β1- and carbachol-treated cells above those in TGF-β1-treated
cells alone (Fig. 3A, top). IBMX treatment decreased MLC phosphorylation in TGF-β1and carbachol-treated cells to a level similar to that of vehicle control (Fig. 3A, bottom
right).
We next investigated the role of PDE activity in TGF-β1-mediated decreases in
ISO-induced cAMP (Fig. 3B). Vehicle- or TGF-β1-treated HASM cells were pre-treated
with IBMX prior to ISO stimulation. IBMX pretreatment significantly elevated ISO-induced
cAMP levels in TGF-β1-treated HASM cells (Fig. 3B).

TGF-β1 Induces PDE4D Gene Expression in a Dose-Dependent Manner
To determine the extent to which PDEs contribute to β2-agonist hyporesponsiveness in TGF-β1-treated HASM cells, we investigated the expression of HASM
cell-specific PDEs in TGF-β1-treated HASM cells (Fig. 4D) (204). TGF-β1 selectively
increased PDE4D gene expression in a dose-dependent manner. Furthermore, inhibition
of TβR-I receptor signaling with SB-431542 pretreatment in HASM cells blocked PDE4D
gene expression evoked by TGF-β1.
To further determine the extent to which TGF-β1 modulates PDE4D to decrease
β2-agonist-induced relaxation responses, cAMP accumulation, MLC phosphorylation,
and cell stiffness were measured in HASM cells treated with the PDE4 inhibitor
roflumilast (Fig. 4B-D). Roflumilast pretreatment rescued blunted ISO-stimulated cAMP
levels in TGF-β1-treated cells (Fig. 4B). In the presence of roflumilast, TGF-β1-induced
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MLC phosphorylation in ISO-stimulated cells showed little increase over vehicle control
(Fig. 4C, Supplemental Fig. 3B). Additionally, roflumilast pretreatment decreased
augmented HASM cell stiffness in TGF-β1 and ISO-stimulated HASM cells (Fig. 4D).

TGF-β1-Decreases β2-Agonist-Induced Relaxation Responses in a Smad3-Dependent
Manner
The canonical TGF-β1 signaling pathway involves the activation of Smad2/3–
intracellular signaling proteins that mediate a variety of TGF-β1’s effects on HASM cell
signaling in asthma (149). To determine the role of Smad2/3 proteins in TGF-β1mediated inhibition of HASM cell relaxation responses, we investigated TGF-β1’s
modulation of ISO-induced cAMP levels in Smad2/3 siRNA-transfected cells (Fig. 5).
ISO-induced cAMP was significantly increased in Smad3 siRNA-transfected cells in the
presence and absence of TGF-β1 treatment (Fig. 5A). TGF-β1 blunted ISO-induced
cAMP levels in HASM cells transfected with non-targeting and Smad2 siRNA, but had
little effect on ISO-induced cAMP levels in Smad3 siRNA-transfected HASM cells.
To determine the role of Smad2/3 signaling in TGF-β1-mediated induction of
PDE4D gene expression, PDE4D gene expression was investigated in Smad2 or Smad3
siRNA-transfected HASM cells following overnight TGF-β1 treatment (Fig. 5B). PDE4D
gene expression was significantly increased in TGF-β1-treated HASM cells. However,
PDE4D gene expression in Smad2 and Smad3 siRNA-transfected cell was not
significantly different than non-targeting siRNA control (Fig. 5B).
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Discussion

In the present study, we demonstrate that TGF-β1 attenuates β2-agonist-induced
relaxation responses in HASM cells. To date, TGF-β1 has been shown to negatively
modulate β-adrenergic responses in multiple cell types (196, 197, 205, 206). Here, we
demonstrate that TGF-β1 treatment – in the presence or absence of the contractile
agonist carbachol – significantly attenuates ISO-induced HASM cell relaxation via
increased cell stiffness and MLC phosphorylation (Fig. 1). While we only saw a modest
decrease in β2-agonist-induced hPCLS relaxation in TGF-β1-treated slices, this may be
due to inhibitory feedback from surrounding epithelium present in the slice
(Supplemental Fig. 2) (138). As these hPCLS experiments were conducted in slices
obtained from subjects without asthma, it is possible that these feedback mechanisms –
and the extent of TGF-β1-induced β2-agonist insensitivity - would be altered in slices
obtained from subjects with asthma (168, 207–209). Nevertheless, in this study, we
observe that TGF-β1 consistently attenuates β2-agonist-induced responses in HASM
cells. While previous studies suggest that TGF-β1 modulates β2AR responses through a
protein synthesis-dependent mechanism, the details by which this modulation occurs is
not fully understood (196, 197). For the first time, we demonstrate that TGF-β1’s effects
on HASM cell relaxation responses occur via a Smad3 and PDE4D-dependent pathway.
Collectively, our findings further establish TGF-β1 as a mediator of bronchodilator
resistance via modulation of downstream cAMP pathway effects.
Previous

studies

suggest

that

TGF-β1

attenuates

ISO-induced

cAMP

accumulation by modulating β2AR number and gene expression (196, 197). However,
our data suggest an additional mechanism for the attenuation of cAMP by TGF-β1. In
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our study, TGF-β1 blunted cAMP induced by both ISO and PGE2, a mediator that binds
to the Gs/(Gi)-associated prostaglandin EP2 and EP4 G protein-coupled receptors to
elevate intracellular cAMP levels (Fig. 2A) (210). Little is known regarding TGF-β1’s
effects on EP receptor expression in HASM, and it is unlikely that TGF-β1 blunts HASM
cell cAMP by decreasing the expression of two independent Gs-coupled receptors.
Interestingly, previous studies suggest a role for TGF-β1 in modulating G protein
function. Treatment with pertussis toxin, an irreversible Gi inhibitor, blocked TGF-β1induced PGE2 production in human lung fetal fibroblasts (211). Additionally, a report
demonstrating an augmentation of cholera- and pertussis toxin-induced ADP-ribosylation
in TGF-β1-treated rat osteoblast-like cells suggests that TGF-β1 alters the abundance of
both Gs and Gi proteins (212). TGF-β1 also modulates the expression of guanine
nucleotide exchange factors (GEF) – proteins that regulate the activity of small G
proteins – in various cells (213, 214). A study in murine fibroblasts suggests that TGF-β1
increases GTPase activity via a pertussis-sensitive mechanism (215). Further studies
will be needed to investigate whether TGF-β1 modulates G protein expression or activity
in HASM cells, and whether this potential modulation further affects HASM cell
relaxation responses. However, our present results suggest that TGF-β1 – in addition to
attenuating β2AR function – works downstream of the receptor level to impair ISOstimulated cAMP levels.
We used forskolin – a direct activator of adenylyl cyclase – as a tool to further
investigate TGF-β1’s downstream effects on the cAMP signaling pathway (216). In this
study, TGF-β1 did not significantly alter forskolin-stimulated cAMP levels in HASM cells
(Fig. 2B). Current literature suggests an unclear role for TGF-β1 in modulating adenylyl
cyclase activity. In previous reports using human and guinea pig airway smooth muscle,
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TGF-β1 treatment induced little or modest reductions in forskolin-stimulated cAMP
accumulation (196, 206). Curiously, other reports demonstrate that chronic cytokine
treatment sensitizes adenylyl cyclase in HASM (217). In these studies, chronic
incubation of HASM cells with the cytokine IL-1β or TNF-a caused a 2- to 3-fold increase
in forskolin-stimulated cAMP (217, 218). It is posited that adenylyl cyclase sensitization
may be a feedback response to upregulate relaxation pathways in the face of cytokineinduced

airway

hyperresponsiveness

(218).

As

TGF-β1

induces

HASM

cell

hyperresponsiveness (202) and modestly augments forskolin-stimulated cAMP in our
study (Fig. 2B), further studies will be needed to determine the effect of TGF-β1 on
adenylyl cyclase activation.
As we did not observe that TGF-β1 negatively regulates adenylyl cyclase
function in HASM cells, we next investigated the role of cAMP-hydrolyzing PDE
enzymes in TGF-β1’s attenuation of HASM cell relaxation responses. Previous reports
suggest that TGF-β1 modulates PDE4 expression and activity. In human alveolar
epithelial cells, TGF-β1 upregulated PDE4 mRNA, protein expression, and total cAMPPDE activity (219). TGF-β1 also mediates fibronectin, collagen I, and connective tissue
growth factor induction in bronchial rings via a PDE4D-dependent mechanism (220). In
human fetal lung fibroblasts, TGF-β1-induced collagen gel contraction, fibronectin
release, and fibroblast chemotaxis was inhibited in the presence of PDE4
pharmacological inhibitors (221). Therefore, we aimed to further investigate the role of
PDE4 in the attenuation of ISO-induced cAMP by TGF-β1.
We demonstrate that TGF-β1 selectively induces PDE4D gene expression in
HASM cells, and that PDE4D inhibition rescues attenuated ISO-induced cAMP levels in
HASM cells (Fig. 4A, 4B). While roflumilast only modestly enhanced ISO-mediated
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decreases in TGF-β1-induced MLC phosphorylation (Fig. 4C), roflumilast significantly
enhanced ISO-induced, single-cell relaxation in TGF-β1-treated HASM cells (Fig. 4D).
While discrepancies between biochemical and cell stiffness measurements in
roflumilast-treated HASM cells are puzzling, studies suggest that both actomyosin crossbridge cycling – regulated by MLC phosphorylation - and actin polymerization (173, 222)
mediate HASM cell contractile responses. Reports demonstrate that TGF-β1 induces
both MLC phosphorylation (202, 213) and actin polymerization (114, 223) in HASM cells.
While the individual contributions of these pathways to HASM cell shortening remain
unclear, both pathways are modulated by cAMP signaling (203, 224). Evidence suggests
that PDEs shape compartmentalized cAMP signaling in the cell, where subcellular PDE
localization mediates variations in cAMP-stimulated responses (192, 204, 225). As both
PDE3 and PDE4 hydrolyze cAMP in HASM, the observed discrepancy may result from
the relative contribution of cAMP signaling to each pathway, driven by the spatialmediated effects of PDE isoforms.
To further determine the mechanism by which TGF-β1 attenuates ISO-induced
responses, we investigated the role of the canonical TGF-β1 signaling pathway via
Smad2/3 in HASM cells (Fig. 5). In non-targeting and Smad2 siRNA-transfected cells,
ISO-stimulated cAMP was decreased following TGF-β1 treatment (Fig. 5A). In Smad3
siRNA transfected cells – however – TGF-β1 had little effect on ISO-induced cAMP.
Additionally, knockdown of Smad3 augmented ISO-stimulated cAMP levels in HASM
cells.
The observed augmentation of ISO-stimulated cAMP may indicate that Smad3
knockdown attenuates TGF-β1 receptor activity resulting from the release of biologically
active TGF-β1 in HASM cells at baseline (75). Alternatively, it is possible that Smad3
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knockdown augments basal cAMP levels through its association with HASM cell
microtubules. Smad3 has been reported to bind directly to microtubules in the absence
of TGF-β1 signaling (226), and TGF-β1 can induce microtubule stability in a variety of
cell types (227, 228). Therefore, impaired TGF-β1 signaling via Smad3 knockdown may
exert destabilizing effects on microtubule stability.
Microtubule

destabilization

has

been

correlated

with

impaired

cAMP

accumulation in multiple cell types. The microtubule assembly inhibitor colchicine
induces cAMP generation in human leukocytes in a dose-dependent manner (229). In
human leukocyte and S49 lymphoma cell studies, multiple microtubule assembly
inhibitors enhanced β-adrenergic and prostaglandin-stimulated cAMP accumulation in a
time- and dose-dependent manner, potentially by acting on microtubules that inhibit AC
activity (230, 231). However, further studies are needed to determine the significance of
the interaction between Smad3 and microtubules in HASM cells, and how this interaction
may affect microtubule stability and cAMP generation.
In addition to modulating HASM cell cAMP levels, Smad2/3 knockdown also
decreased augmented PDE4D gene expression in TGF-β1-treated cells (Fig. 5B). In
both Smad2- and Smad3-transfected HASM cells, PDE4D gene expression was not
significantly different between cells treated with vehicle versus TGF-β1 overnight.
Collectively, our Smad2/3 knockdown results support previous studies demonstrating
that Smad2 and Smad3 exert differential effects on cell function (176, 177, 202).
Additionally, our findings demonstrate a definitive role for TGF-β1 and Smad signaling in
decreased HASM cell relaxation responses.
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Due to the breadth and complexity of TGF-β1 signaling, there may be additional
pathways by which TGF-β1 attenuates HASM cell cAMP levels that we did not
investigate in this study. Other cytokines that attenuate HASM cell relaxation responses
– such as IL-1B – attenuate ISO-induced cAMP via COX-2 induction and prostanoid
release (232, 233). As TGF-β1 induces COX-2 expression in HASM cells (128), it is
possible that prostanoid induction contributes to TGF-β1’s impairment of relaxation
responses. Further studies will be needed to determine the contribution of potential TGFβ1 signaling pathways in HASM cell relaxation responses.
In conclusion, our study further establishes TGF-β1 as a mediator of
bronchodilator resistance in asthma via a Smad3-dependent pathway (Fig. 6). In light of
our previous work on TGF-β1-induced hyperresponsiveness in HASM, these results
further suggest TGF-β1 to be a promising therapeutic target to increase bronchodilator
sensitivity and attenuate airway obstruction in asthma.
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Figure Legend

Figure 1. TGF-β1 Decreases β2-Agonist-Induced Relaxation in HASM Cells. A)
Isolated HASM cells were stimulated with ISO in the presence or absence of TGF-β1 (10
ng/mL, 18 h) (N= 3 donors +/-SEM). B) Phosphorylated MLC following TGF-β1 (10
ng/mL, 18 h), carbachol (Cch, 20 μM), and/or isoproterenol (ISO, 1 μM; bottom)
treatment (N=4-7 +/-SEM). *P < 0.05

Figure 2. TGF-β1 Blunts Agonist-Induced cAMP Levels. A) HASM cells were pretreated with TGF-β1 (10 ng/mL) overnight and acutely stimulated with ISO (1 μM, 5 min)
(N=7 +/- SEM; ISO 1 μM: 3684.2 +/- 1170.0 pmol/well), PGE2 (100 nM; 5 min) (N=4
donors +/-SEM; PGE2: 40270.4 +/- 25537.2 pmol/well), or B) Forskolin (10 μM; 15 min)
(N=3 donors +/-SEM; FSK 10 μM: 7192.4 pmol/well +/- 3244.3) prior to lysis for cAMP
level determination. *P < 0.05

Figure 3. PDE Inhibition Rescues ISO-Stimulated Responses in TGF-β1-Treated
HASM Cells. A) MLC phosphorylation in HASM cells pre-treated with vehicle or TGF-β1
(10 ng/mL; 18h) and/or IBMX (500 μM, 30 min) prior to stimulation with Cch (20 μM; 12
min) and/or ISO (1 μM, 10 min) (N=4 +/-SEM; Max: 23.2 fold change over vehicle +/9.4). B) cAMP levels in TGF-β1 (10 ng/mL; 18h)-treated HASM cells pre-treated with
vehicle (N=7+/-SEM; ISO 1 μM: 3684.2 +/- 1170.0 pmol/well) or IBMX (500 μM, 30 min)
(N=6+/-SEM; IBMX 1 μM ISO: 11927.4 +/- 1599.3 pmol/well) prior to ISO (1 μM, 5 min)
stimulation. N=4 donors +/-SEM. *P < 0.05
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Figure 4. TGF-β1 Induces PDE4D Gene Expression in a Dose-Dependent Manner.
A) PDE gene expression in TGF-β1-treated (10 ng/ml, 18 h) HASM cells (N=3 donors +/SEM). B) cAMP levels in ISO-stimulated HASM cells treated with TGF-β1 (10 ng/mL;
18h) in the presence or absence of roflumilast (RF; 10 μM, 30 min) pretreatment (N=6
+/-SEM; ISO μM: 1281.1 +/- 406.6 pmol/well). C) MLC phosphorylation in TGF-β1 (10
ng/ml 18 h)-treated HASM cells in the presence of roflumilast (RF; 10 μM, 30 min), Cch
(20 μM, 12 min) and/or ISO (1 μM, 10 min) stimulation (N=6 donors +/-SEM). D) HASM
cell stiffness in TGF-β1 (10 ng/ml 18 h)-treated cells in the presence or absence of
roflumilast (RF; 10 μM, 30 min) (N=1 donor; N=223 +/-SEM). *P < 0.05; relative to
vehicle control unless otherwise shown.

Figure 5. TGF-β1-Decreases β2-Agonist-Induced Relaxation Responses in a
Smad3-Dependent Manner. A) cAMP levels in non-targeting (NT) or Smad2/3 siRNAtransfected HASM cells pre-treated with TGF-β1 (10 ng/mL, 18 h) and stimulated with
Cch (20 μM; 10 min) and/or ISO (1 μM, 5 min) (N=4 donors +/-SEM; Max: 15397.2+/3010.4 pmol/well). B) PDE4D gene expression in NT or Smad2/3 siRNA-transfected
HASM cells pre-treated with SB-431542 (5 μM, 30 min) prior to TGF-β1 (10 ng/mL)
overnight treatment (N=3 donors +/-SEM). *P < 0.05

Figure 6. Proposed Role of TGF-β1 in HASM Cell Contractile Responses in
Asthma. TGF-β1 signaling augments basal and HASM cell shortening through a
Smad3, ROCK-dependent pathway as previously described (202). In addition to
modulating HASM cell contractile responses, Smad3 activation increases PDE4D gene
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expression, leading to increased cAMP hydrolysis and blunted HASM cell relaxation
responses. TGF-β1, transforming growth factor beta 1; TβR-I/II, TGF-β receptor I/II;
ROCK, rho-associated protein kinase; RhoA, Ras homolog gene family, member A;
MLCP, myosin light-chain phosphatase; MLCK, myosin light chain kinase; MLC20, 20kDa myosin light chain 20; cAMP, cyclic adenosine monophosphate; 5’AMP, 5’
adenosine monophosphate; PDE4D, phosphodiesterase 4D.
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Supplemental Figure Legends

Supplemental Figure 1. TGF-β1 Decreases β2-Agonist-Induced Relaxation in
HASM Cells. MLC phosphorylation in HASM cells stimulated with ISO and/or Cch in the
presence or absence of TGF-β1 (10 ng/mL, 18 h). Representative immunoblot of seven
separate experiments.

Supplemental

Figure

2.

TGF-β1

Modestly

Decreases

β2-Agonist-Induced

Bronchodilation in hPCLS. hPCLS were treated with TGF-β1 (18 h, 100 ng/mL), precontracted to Cch, and subjected to a Formoterol (Form) dose response (N=7; +/- SEM).

Supplemental Figure 3. PDE Inhibition Decreases TGF-β1-Mediated MLC
Phosphorylation in ISO-Stimulated HASM Cells. A) MLC phosphorylation in HASM
cells pre-treated with vehicle or TGF-β1 (10 ng/mL; 18h) and/or IBMX (500 μM, 30 min)
prior to stimulation with Cch (20 μM; 12 min) and/or ISO (1 μM, 10 min). Representative
immunoblot of four separate experiments. B) MLC phosphorylation in TGF-β1 (10 ng/ml
18 h)-treated HASM cells in the presence of roflumilast (10 μM, 30 min), Cch (20 μM, 12
min) and/or ISO (1 μM, 10 min) stimulation. Representative immunoblot of six separate
experiments.
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TGF-β1 as a Therapeutic Target in Asthma: Advantages and Limitations

In this study, we establish TGF-β1 as a promising novel target for reducing
asthma exacerbations and increasing β2-agonist sensitivity. Altered TGF-β1 signaling
plays a role in the pathogenesis of many diseases. As TGF-β1 signaling is frequently
altered in tumor cells, however, inhibitors of TGF-β1 signaling have been most widely
studied in the context of cancer therapy. Nevertheless, no direct inhibitors of TGF-β1
signaling have been FDA approved thus far.
The pleotropic nature of TGF-β1 signaling makes it a challenging therapeutic
target. In the context of cancer, TGF-β1 exerts anti- or pro-oncogenic effects on earlyand late-stage tumors, respectively, depending on the stage of tumor development
(234). However, cancer cells can eventually escape the inhibitory effects of TGF-β1, and
TGF-β1 overexpression at later development stages results in enhanced tumor
progression. Therefore, TGF-β1 antisense oligonucleotides, anti-TGF-β1 vaccines, TGFβ1 monoclonal antibodies, small molecule TGF-β1 receptor kinase inhibitors, Smad2/3
peptide aptamers, and expression of soluble TBRII/III as decoy receptors have all been
explored in pre-clinical or clinical trials with some promising results (235, 236). While
most clinical trials to date have reported positive safety and efficacy results, some antiTGF-β1 vaccine studies reported adverse effects in 10% of patients, including fatigue,
nausea, headaches, and cough (237). In clinical trials of an anti-TGF-β1 monoclonal
antibody, adverse events included gastrointestinal symptoms and gingival bleeding
(238).
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Within the field of asthma, TGF-β1 as a therapeutic target has yet to be explored.
However, several FDA-approved monoclonal antibodies targeting the cytokine IL-5, a
mediator of eosinophil maturation and survival/recruitment to the airway, effectively
reduce airway exacerbations. While these antibodies effectively decrease eosinophil
counts and exacerbation rates in severe eosinophilic asthma, they have variable effects
on asthma control, lung function, and health status (239, 240). However, these drugs are
well-tolerated, with common adverse effects including headache, nasopharyngitis, and
fatigue (241).
Together, the success of these inhibitors further suggests TGF-β1 as a promising
target for decreasing asthma exacerbations in severe eosinophilic asthma. As airway
structural cells from patients with asthma exhibit increased TGF-β1 expression, TGF-β1
may be a potential novel target for decreasing exacerbations in both eosinophilic and
non-eosinophilic severe asthma (242). Due to the complexity and ubiquitous nature of
TGF-β1 signaling, however, the design and dosing strategy of TGF-β1-targeting
therapeutics will need to be carefully considered when designing TGF-β1-specific
inhibitors to reduce exacerbations and improve lung function in asthma.
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Future Directions

Our work in HASM has demonstrated that TGF-β1 induces AHR in HASM cells
through a Smad3- and ROCK-dependent pathway. Furthermore, we show that TGF-β1
decreases HASM sensitivity to β2-agonist bronchodilators in a Smad- and PDE4Ddependent manner. In addition to PDE4 activation, PDE3 activation may also modulate
HASM cell relaxation responses (203). While TGF-β1 did not induce PDE3 gene
expression in HASM cells (Fig. 3.4), we did not investigate whether TGF-β1 induces
PDE3 activity. TGF-β1 induction of PDE3 may partially explain why we did not observe a
full rescue of β2-agonist sensitivity after PDE4D inhibition (Fig. 3.4). To investigate
whether increased PDE3 activation plays a role in the attenuation of β2-agonist
responses by TGF-β1, we can investigate relaxation responses in TGF-β1-treated
HASM cells in the presence or pharmacological and siRNA inhibitors of PDE3.
Interestingly, our data suggest that TGF-β1 may modulate G protein expression
or activity in HASM cells. In our AHR studies, we consistently observed a synergistic
effect of TGF-β1 and carbachol on HASM cell shortening. This effect was demonstrated
in TGF-β1-treated cells via increased HASM cell shortening in the presence of carbachol
(Fig. 2.2-2.5). As the muscarinic acetylcholine receptor stimulation activates Gαi –
leading to the inhibition of adenylyl cyclase activity – TGF-β1 may augment carbacholinduced contractile responses by modulating Gαi expression or translocation(182).
In our relaxation studies, TGF-β1 decreased both ISO and PGE2-stimulated
cAMP. While PDE4D induction plays an essential role, we do not see a full rescue of
HASM cell relaxation to β2-agonists in the presence of a PDE4D inhibitor. This may be
due to TGF-β1’s role in altering β2AR expression, number, and function (196, 205).
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However, the role of TGF-β1 in decreasing both ISO and PGE2-induced cAMP suggests
a potential effect of TGF-β1 on Gαs expression or activity. TGF-β1 may also induce
PDE4D expression and subsequent β2-agonist insensitivity in asthma by modulating Gi
expression or activity. PDE4D activity in HASM cells from patients with asthma is
regulated by the Gβγ subunit of the Gi protein, suggesting that augmented TGF-β1
signaling in asthma may lead to β2-agonist insensitivity via induction of Gi and PDE4D
(243).
To further explore the mechanisms associated with attenuated β2-agonist
sensitivity in TGF-β1-treated HASM cells, future studies can investigate TGF-β1’s role in
modulating G protein expression. Through gene expression and immunoblot
experiments, we can determine whether TGF-β1 induces Gs or Gi transcript and protein
expression. Furthermore, we can use pharmacological and siRNA inhibitors to assess
contractile and relaxation outcomes in TGF-β1-treated HASM cells. We can also
transfect cells with constitutively active Gαs mutants to determine whether we still
observe attenuated relaxation responses in TGF-β1-treated HASM cells(244).
Interestingly, TGF-β1 has also been shown to modulate the expression of guanine
exchange factors (GEFs), proteins that regulate G protein activity, in HASM cells (213).
If TGF-β1 has little effect on G protein expression or activity, we can use
pharmacological and siRNA inhibitors to investigate the role of TGF-β1 in modulating the
expression of associated GEFs or GTPase-activating proteins (GAPs). Together, these
studies will give us a better grasp on the role of TGF-β1 in HASM cell contraction and
relaxation, as well as the role of TGF-β1 in modulating G protein and GPCR function.
In this dissertation, we did not explore the role of TGF-β1 in mediating
glucocorticoid resistance. However, previous studies suggest that TGF-β1 decreases
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glucocorticoid responses in HASM cells (245, 246). To further investigate the role of
TGF-β1 in glucocorticoid resistance, we can further define these results by immunoblot,
and investigate the necessity of Smad2/3 signaling for the attenuation of steroid effects
by TGF-β1 using Smad siRNA. Other cytokines that mediate steroid resistance work by
modifying glucocorticoid receptor beta translocation and expression, or by inducing
interferon regulatory factor 1 (247, 248). Future immunoblot studies can be conducted to
determine whether TGF-β1 induces steroid resistance via these same mechanisms.
Finally, our lab and others have demonstrated that HASM cells isolated from
patients with asthma are different than those isolated from patients without asthma (168,
207–209). In this dissertation, we did not investigate the effect of TGF-β1 on cells from
patients with asthma. It is possible that, by using cells from patients with asthma, we
might observe more dramatic effects on AHR and β2-agonist sensitivity than what we
observe in HASM cells from normal lung donors. Additionally, the modest β2-agonist
sensitivity we observe in TGF-β1-treated hPCLS isolated from normal lung donors may
indeed be a more significant effect in hPCLS isolated from fatal asthma lung donors.
Further studies will be needed to tease out the differences between non-asthma and
fatal asthma HASM cells when it comes to TGF-β1-induced AHR and attenuation of β2agonist responses.
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Conclusions

The factors contributing to AHR, a defining characteristic of asthma, have yet to
be completely elucidated. Repeated asthma exacerbations can lead to sustained AHR
that remains insensitive to bronchodilator therapy. In this dissertation, we have
established TGF-β1, a cytokine elevated in the airways of patients with asthma, as a
novel therapeutic target for reducing asthma exacerbations in severe asthma. TGF-β1
exerts its effects on both sides of AHR by contributing to increased HASM cell
shortening and decreased responsiveness to bronchodilators. As current upcoming
therapeutics targeting TGF-β1 show promising effects, our studies further establish TGFβ1 as a viable target to reduce exacerbations and improve lung function in patients
resistant to current therapeutics.
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